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Abstract
Antigen presenting cells (APCs) perform the essential task of integrating responses
between the innate and adaptive immune system. Several approaches have been
undertaken to manipulate the effects of APCs for therapeutic purposes. Panax
notoginseng is a medicinal herb that is purported to possess a number of properties
including modulation of the immune system. However, limited information exists on the
effects and toxicities of this herbal on APCs. In this regard, we assessed the effects of
Panax notoginseng on the fate and function of professional APCs in murine models using
macrophages and dendritic cells (DCs). APCs were stimulated with the toll-like receptor
ligands LPS, CpG and poly(I:C) and treated with notoginseng (0-200 µg/ml). The LPS
induced levels of the proinflammatory cytokine TNF-α, as well as the expression of
accessory molecules MHC II, CD40 and CD86, were decreased dependent on
notoginseng exposure time-points relative to LPS stimulation. LPS induced IL-1β, IL-6
and IL-12 production was also decreased with concurrent notoginseng treatment for 24
hours. Notoginseng decreased TNF-α and CD40 activation by CpG and poly(I:C), but
had varied effects on the induction of IL-6 and CD86. Furthermore, treatment of APCs
with ginsenosides Rb1 and Rg1 had differential effects on the production of TNF-α and
IL-6. Phagocytosis of FITC-conjugated ovalbumin antigen by DCs was decreased by
notoginseng. Furthermore, the uptake of FITC-conjugated modified LDL was reduced in
notoginseng treated DCs. However, T cell proliferation in response to notoginsengtreated-antigen-loaded DCs was not affected in vitro or in vivo. Mechanistically,
notoginseng reduced nuclear levels of the transcription factor NFκB, but had no effect on
glucocorticoid receptor activation. No immunotoxicities were observed with low dose
notoginseng (660 µg/kg) treatment of Balb/c mice in vivo. Collectively, our results
indicate that notoginseng decreased inflammatory mediator production by APCs, without
altering their ability to induce antigen specific CD 4+ T cell proliferation. Our research
provides insight into the potential use of this herbal in the treatment of inflammatory
diseases as a safe and effective complement to existing remedies.
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CHAPTER 1
Introduction
This study describes the effects of the medicinal herb Panax notoginseng
(notoginseng) on the fate and function of professional antigen presenting cells (APCs).
This introductory chapter will (1) outline the organization and function of the immune
system with primary focus on APCs, Toll-like receptors (TLRs) and inflammation, (2)
provide detailed information about the general properties and uses of plants in the
Ginseng species, and (3) elucidate modes by which notoginseng modulates immune
function.

Overview of the Immune System
The immune system is designed to eliminate any object that is characterized as being
foreign or a danger to the body (Goldsby et al., 2003). This includes protection from
invading microorganisms such as bacteria, viruses and fungi, as well as eliminating cells
with altered proteins or other molecules that are no longer recognized as “self”.
Surveillance of an individual involves a complex process, with various hierarchies and
checkpoints existing to facilitate immune efficiency. These hierarchies begin with the
immune system being divided into two sections, innate and adaptive immunity (Parkin
and Cohen, 2001). These sections are not mutually exclusive, but work in conjunction
with each other to effectively eliminate threats to the body. The innate arm of immunity
recognizes non-specific threats and reacts immediately to danger patterns and signals.
Alternatively, the adaptive arm is the precision arm and recognizes specific molecules
that are capable of binding to adaptive immune cell receptors. These molecules are
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known as antigens. However, as specificity takes time, there is a lag between the
immediate, but non-specific, innate response and the precise, but slower, adaptive
immune response.
Innate immunity
Innate immunity is composed of four types of defensive barriers: anatomic,
physiologic, phagocytic and inflammatory (Goldsby et al., 2003). The anatomic barrier
encompasses the skin and mucous membranes. This barrier is the first line of defense and
prevents the entry of microorganisms into our body. Physiological barriers include the
body’s ability to control temperature, pH and chemical mediators whose primary function
is to target pathogens and create an environment that is not conducive to their growth.
The third line of innate defense mechanism is the ingestion (phagocytosis) and
destruction of pathogens by phagocytes. Specialized immune cells such as monocytes,
macrophages, neutrophils and dendritic cells conduct phagocytosis. There are also
immune cells whose primary function is to present pieces of phagocytosed pathogens,
known as antigens, to adaptive immune cells. These cells are known as antigen
presenting cells (APCs) and will be discussed further in detail later in this chapter. The
fourth defensive strategy used by our innate cells is the production of an inflammatory
environment. This environment is created when leukocytes and inflammatory molecules
converge on sites of infection or tissue injury. While this process is advantageous to
clearing insults to tissue injuries, persistence of an inflammatory response can lead to
chronic inflammatory diseases. The implications of inflammation and an overactive
immune response will also be discussed below.
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Antigen presenting cells (APCs)
APCs are specialized immune cells that express major histocompatibility complex
(MHC) II molecules on their cell surface and can process and present foreign substances
known as antigens, which binds to these molecules to elicit adaptive immunity (Goldsby
et al., 2003). These MHC II molecules are important because T cells recognize antigens
only when bound to a MHC complex. This presentation of antigens by APCs to T cells is
widely referred to in immunology as “signal 1”. The “second signal” involves APCs
delivering co-stimulatory signals to T cells that are essential for their full activation.
These two processes are known in immunology as the two-signal hypothesis (Fig. 1-1).
In addition to these signals, activated APCs also release a third signal known as
cytokines. Cytokines are small protein molecules that mediate numerous physiological
responses including the development of specific T cell responses, modulation of
inflammation, regulation of hematopoiesis and control of cell proliferation and
differentiation (Goldsby et al., 2003). The activation process begins when an APC
encounters antigen in the periphery. Uptake of antigens can trigger the migration of
certain APC types to a secondary lymphoid organ. There, antigen-bearing APCs select
antigen-specific lymphocytes from a pool of recirculating T cells. Under the right
conditions, interaction of this APC with T cells initiates an adaptive immune response.
The three major types of APCs in order of importance are dendritic cells (DCs),
macrophages and B cells. DCs are known as the primary professional APCs of the
immune system (Trombetta and Mellman, 2005). These cells are unique for a number of
reasons the main one being that DCs are the most potent APCs capable of inducing the T
cell-mediated immunity, thus permitting the establishment of immunological memory
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(Banchereau et al., 2000c; Foged et al., 2002; Gilboa and Vieweg, 2004). DCs
constitutively express high levels of MHC molecules, as well as high levels of the
costimulatory molecules CD80 and CD86 that are needed to initiate the T cell response.
As a result, DCs are potent activators of naïve, memory and effector T cells. Under
different microenvironments DCs are able to induce contrasting states of immunity or
tolerance.
DCs mainly reside in peripheral tissues. Upon encountering a danger signal, these
cells mature into potent APCs and migrate to draining lymph node organs where they can
interact with T cells (Kooten van and Woltman, 2004). The maturation process results in
decreased capacity to capture antigen, but increased expression of the activation
molecules CD40, CD86 and MHC II (Kooten van and Woltman, 2004). These changes
in DC morphology are important for increasing their interactions with corresponding
receptors on the surface of T cells to facilitate activation of the adaptive immune system.
The major types of DC subsets are lymphoid and myeloid, in addition, interstitial and
Langerhans DC subsets maybe also be present dependent on animal type (Banchereau et
al., 2000c). In previous years, there have been numerous studies on a new type of DC
being present in both species, now known as plasmacytoid DCs (Colonna et al., 2004;
Zhang and Wang, 2005). All DC subsets differ in phenotype, localization and function.
The traditional DC subsets express appreciable levels of the classic cell surface molecules
MHCII and CD11c by which they can be identified by using tagged antibodies against
these proteins. However, plasmacytoid DCs do not express CD11c in humans and express
it at very low levels in mice (Colonna et al., 2004).
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DCs can be differentiated and expanded from progenitor cells by using the growth
factors FMS-like tyrosine kinase 3 ligand (Flt3-L) and granulocyte macrophage-colony
stimulating factor (GM-CSF) (Banchereau et al., 2000c). Flt3-L targets primitive
hematopoetic bone marrow progenitors, inducing their expansion and differentiation with
all DC subsets increasing dramatically. In contrast, GM-CSF preferentially expands
myeloid DC subsets. Unlike DCs, macrophages do not express MHC II and costimulatory
molecules constitutively, but induces them after their activation by phagocytosis of
microbes such as bacteria or viruses. This means that while DCs are the most important
cells in naïve T cell and B cell activation, unstimulated macrophages do not activate these
cells as efficiently. In addition to antigen presentation, macrophages influence a range of
immune responses by antigen recognition, capture, clearance and transport (Gordon,
1998). The function and activity of macrophages is strongly influenced by their
microenvironment (Gordon, 1998; Laskin et al., 2001). The liver and lung have the
largest populations of macrophages in the body (Laskin et al., 2001). As a result of the
unique attributes of these tissues, hepatic and pulmonary macrophages play essential
roles not only in nonspecific host defense mechanisms, but also in the homeostatic
responses of these tissues (Laskin et al., 2001).
The third type of professional APCs is the B cell. Among the APCs B cells are least
likely to uptake and present antigens. In fact, they are better known for their adaptive
immune functions as opposed to their APC capability. As such, their functions will be
discussed in the section on adaptive immunity later in this chapter.
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Figure 1-1.

APC

APC
CD86

Figure 1-1. The two signal hypothesis of T cell activation. APCs activate helper T
cells by the binding of the MHC II/antigen complex to the T cell receptor. This process is
known as signal 1. Signal 2 involves the binding of costimulatory molecules on the APC
such as CD86 with CD28 on the helper T cell. Other signals such as cytokine production
by the APC also aid in the activation process. This figure was adapted from Seely et al.
2003, Anatomy and Physiology, Mc-Graw Hill Companies, pg 805.
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Toll-like receptors (TLRs)
Certain types of molecules are unique to microbes and are never found in multicellular
organisms. Innate immune cells have evolved to recognize these pathogen associated
molecular patterns (PAMPS) using pattern recognition receptors (PRRs) (Doyle and
O'Neill, 2006). PAMPS are highly conserved within microbial species, but are generally
absent from human cells. Of these classes of receptors, the TLRs are among the most
important. The TLR family of proteins is an ancient one, recognizing generations of
defensive responses to pathogens in organisms as widely separated in evolution as
humans and flies. Over ten different types of TLRs have been recognized, each being
activated by a wide array of PAMPs (Fig.1-2). These TLRs are characterized by the
presence of an extracellular leucine-rich repeat domain (LRR) and an intracellular
Toll/IL-1 receptor (TIR) domain (Carpenter and O'Neill L, 2007). In mammals, many
TLR receptors are found on the cell membranes of innate immune cells such as
macrophages and DCs. However, TLR3, 7, 8 and 9 are expressed in intracellular
compartments, principally in the endosomes and the endoplasmic reticulum (Carpenter
and O'Neill L, 2007; Kanzler et al., 2007). TLRs are either constitutively expressed or
induced in different cell types, which determines their capacity for microbial detection
(Napolitani et al., 2005). TLRs are differentially coupled to a number of cell signaling
pathways. However, with the exception of TLR3, all TLRs are coupled to the myeloid
differentiation primary-response protein 88 (MyD88) adaptor; TLR3 and TLR4 are also
coupled to TIR-related adaptor protein inducing interferon (TRIF) (Kanzler et al., 2007;
Napolitani et al., 2005). Signaling through TLRs leads to the activation of transcription
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Figure 1-2.

Figure 1-2. The initiation of the immune responses by TLRs activated by microbial
ligands. TLR signaling is initiated by distinct PAMPS. This activation ultimately leads to
inducing downstream transcription factors responsible for initiating a variety of immune
mediators. This figure was obtained from (Carpenter and O'Neill L, 2007).
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molecules including nuclear factor kappa B (NFκB) and interferon response factor 3
(IRF-3) which in turn culminates in activation and synthesis of a range of proinflammatory mediators including cytokines, co-stimulatory molecules and inflammatory
enzymes (Doyle and O'Neill, 2006). Recent studies on TLRs also include enhanced roles
that these receptors play in immune cell physiology such as enhanced antigen capture via
induction of actin remodeling of the cytoskeleton of DCs (West et al., 2004). As a result
of these unique immunomodulatory properties of TLRs, new trends in medicine have
sparked interest in the development of TLR agonists in the treatment of cancer, viral
infections and as an adjuvant in potent new vaccines (Kanzler et al., 2007; Wickelgren,
2006). In addition, as recognition of inappropriate TLR responses in autoimmunity and
inflammation grows, efforts have begun to develop antagonists to Toll-like receptors as a
treatment for immune related diseases (Kanzler et al., 2007; Marshak-Rothstein and
Rifkin, 2007).

Inflammation
Tissue damage from an injury or by an invading microorganism induces a complex
sequence of events collectively known as the inflammatory response. The response is
simply characterized as involving redness, swelling, heat and pain, which are classic
symptoms from the three major events in inflammation. These events are vasodilation,
increased capillary permeability and influx of phagocytes from the capillaries into the
damaged tissue to attack pathogens. Inflammation allows immune cells to quickly and
efficiently travel to sites of infection, where they can target and eradicate pathogens.
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While the immune system is important for protecting us against pathogens and
opportunistic organisms, there are some incidences where it is not kept in check. This
condition is known as autoimmunity and primarily involves a hyperactive immune
response to the body’s own antigens. Autoimmunity is primarily characterized by chronic
symptoms of inflammation which causes discomfort and leads to many different disease
conditions such as rheumatoid arthritis, diabetes mellitus type 1 and lupus erythematosus.
In addition to autoimmune diseases there are other conditions such as atherosclerosis,
with components of inflammation being primarily responsible for exacerbation of the
diseases (Vanderlaan and Reardon, 2005). In atherosclerosis, both the innate and adaptive
immune system participate in the exacerbation of the disease. Macrophages and vascular
smooth muscle cells are involved in retaining and modifying lipids in the vessel walls, as
well as driving the chronic vascular inflammation that characterizes this disease
(Vanderlaan and Reardon, 2005).
There are many natural and synthetic agents that are currently used in the treatment of
inflammatory diseases. In spite of this, there is still a constant search for better agents to
treat inflammation. Presently, anti-inflammatory agents target many aspects of the
immune system including cytokines, inflammatory enzymes and transcription factors
responsible for inducing or decreasing the production of these inflammatory mediators.
The most widely used are the non-steroidal anti-inflammatory agents (NSAIDs) and
steroidal anti-inflammatory agents, primarily the glucocorticoid receptor (GCR) agonists.
These agents can also target activation of the transcription factor, NFκB.
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Nuclear Factor Kappa B (NFκB)
NFκB is a family of transcription factors involved in stress-induced, immune and
inflammatory responses (Dixit and Mak, 2002). These molecules also play important
roles in the development of hematopoietic cells and lymphoid organs (Dixit and Mak,
2002).

NFκB is described as being one of the most studied transcription factors in

biology (Dixit and Mak, 2002).
Members of the NFκB family are formed by a dimeric combination of subunits and
are activated by a number of receptor-mediated signaling pathways (Dixit and Mak,
2002). There are five members of this family of transcription factors, Rel (c-Rel), Rel A
(p65), Rel B, NFκB1 (p105/p50) and NFκB2 (p100/p52). These proteins work together
to regulate the expression of genes that encode cytokines, chemokines and adhesion
molecules thereby coordinating adaptive and immune responses. NFκB/Rel dimers
interact with a group of inhibitory proteins called the IκB family. These proteins anchor
NFκB complexes in the cytoplasm in its inactive form (Karin and Ben-Neriah, 2000b).
The degradation of an IκB complex initiated by an inflammatory stimulus leads to the
translocation of NFκB into the nucleus. Inside the nucleus, NFκB complex can bind to
DNA to induce the transcription of immune and inflammatory genes.
Recently, there have been a number of studies on agents that target the activation of
NFκB (Tanaka et al., 2007). From a biomedical standpoint, controlling the activity of this
transcription factor is a prime target for modulating a wide array of immune and
inflammatory genes in numerous diseases (Celec, 2004b).
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Adaptive immunity
As mentioned before, innate immune cells also deliver messages to adaptive immune
cells so they can aid in the fight against pathogens. These adaptive immune cells are
capable of selective recognition and elimination of pathogens. Lymphocytes exclusively
display characteristics of antigen specificity, diversity, immunologic memory and
self/nonself recognition. They distinguish subtle differences among antigens, recognize a
tremendous number of unique structures, remember a pathogen for a faster response time
upon a secondary encounter and can tell the difference between self and foreign
molecules. Adaptive immunity is mediated by two types of cells, T lymphocytes and B
lymphocytes (Fig 1-3).

B cells
B cells are the antibody producing cells of the immune system (Parkin and Cohen, 2001).
Antibodies are glycoprotein molecules with tremendous specificity for antigens. These
glycoprotein molecules are the mediators of humoral immunity. Mature B cells leave the
bone marrow expressing membrane-bound immunoglobulin antibody (Fagarasan and
Honjo, 2000). These naïve B cells circulate in the blood and lymph and are eventually
carried to the spleen and lymph nodes where they reside. When an antigen specific to its
membrane-bound antibody activates a B cell, it can proliferate and differentiate into
antibody secreting cells known as plasma cells or form long-lived memory B cells.
During this stage, affinity maturation and class switching occurs. Affinity maturation
increases the average affinity of the antibody for a specific antigen while class switching
involves a change in the "effector" isotype of the antibody that the B cell produces.
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Figure 1-3.

Figure 1-3. The role of T and B lymphocytes in immunity. An outline of B and T cells
from development to activation, and their effector responses. This figure was obtained
from (Parkin and Cohen, 2001).
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Depending on the nature of the antigen, B cell activation can occur via two different
routes, namely T cell-dependent and T cell-independent responses. The T cell-dependent
response requires direct contact with T helper (Th) cells. This process entails antigens
binding directly to the B cell surface immunoglobulin (Ig), along with costimulation by
antigen-specific T cells through CD40-CD40 ligand interaction and the secretion of
cytokines (Fagarasan and Honjo, 2000). This is followed by appropriately activated B
cells proliferation and differentiation into plasma cells and memory cells. T celldependent immune responses usually involve conventional (B2) B cells. However,
another subset of B cells, B1 cells, along with marginal zone B cells are primarily
responsible for producing antibodies in a T-independent manner (Fagarasan and Honjo,
2000). These cells recognize common bacterial antigens such as LPS as well as selfantigens, such as phosphatidylcholine, DNA and membrane proteins on erythrocytes and
thymocytes. In T cell-independent response by B1 cells, these antigens can activate B
cells in the absence of direct participation with T cells.

Instead, B cell receptors are

effectively cross-linked by antigens with repetitive epitopes, to produce large amounts of
antibodies. These antibodies are usually of lower affinity than those produced by T celldependent responses.
In addition to their primary function as the B cell receptors, antibodies contribute to
targeting proteins on pathogens for elimination by a number of methods. This includes
neutralizing pathogens and opsonization of antigens to enhance clearance of microbes
from the body. The primary properties of antibodies have also led to their use in a variety
of biological industries including research labs and even in the synthesis of many
pharmaceutical agents.
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As previously mentioned, B cells are also considered as professional APCs. However,
of the three professional APCs, B cells are the ones least likely to uptake and present
antigens. This results from a number of factors including the low frequency of naïve B
cells that bear a receptor for a particular antigen, their absence from skin and mucosal
sites through which most pathogens and environmental antigens enter the body, and their
dependence on help from activated CD4 T cells (Rodriguez-Pinto, 2005). In addition to
these factors, even though resting B cells express MHC II molecules, the co-stimulatory
molecule CD86 still has to be induced before they can adequately activate T cells.
However, upon antigen specific activation, B cells become very good APCs, expressing
the necessary accessory/costimulatory molecules and can stimulate naïve, memory as
well as effector T cells.
T cells
Unlike B cells, T cells can only recognize antigen that is bound to MHC molecules on
an APCs. MHC molecules are not important to T cells in antigen recognition only, but
also play a major role in T cell development in the thymus. Antigenic diversity of the T
cell population is limited during maturation by a selection process that only allows MHCrestricted and non-self reactive T cells to mature. The final maturation stages in the
development of most T cells proceed along two different pathways, generating
functionally distinct subpopulations of CD4+ and CD8+ T cells. These populations
recognize different MHC complexes, with CD4+ cells and CD8+ cells being MHC II- and
MHC I- restricted, respectively.
Activation of mature T cells begins with the recognition of a specific antigen in the
context of MHC molecule on an APC, a process known as signal 1 as described in the
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previous section on APCs. In order to be fully activated, there must also be a second
signal involving the interaction of various accessory molecules on the T cell with their
corresponding molecules on the APCs. Following these two signals are a number of
pathway activations leading to the transcription of effector molecules including the
cytokine IL-2, which was originally described as the T cell growth factor (Vincenti and
Luggen, 2007). IL-2 production is sometimes referred to as signal 3 as it induces the
proliferation of T cells into various effector as well as memory T cells when combined
with antigen/MHC molecules and costimulation (Vincenti and Luggen, 2007).
While the activation and differentiation of both CD4+ (T helper-Th) and CD8+ (T
cytotoxic-Tc) cells are vastly similar, there are dramatic differences in the effector
functions of these subsets. Th cells are usually the first T cells activated in an immune
response. These cells orchestrate adaptive immune responses by either primarily
activating B cells for a humoral response or Tc for a cell mediated response. Differences
in the pattern of cytokines secreted by activated Th results in these different types of
immune responses.
As such, Th cells can be classified into two subpopulations distinguished by these
different panels of cytokines which they secrete (Dong and Flavell, 2001). These
populations are referred to as the Th 1 and Th 2 subsets. The Th 1 subset secretes the
cytokines IL-2, IFN-γ, TNF-α and mediates cellular immunity. These events are initiated
by the transcription factor T-Bet which is primarily induced by the presence of high
levels of IL-12 and IL-18 produced by APCs (Gutcher and Becher, 2007). In contrast, Th
2 subsets secrete IL-4, IL-5, IL-10 and IL-13 and regulate humoral immune responses. Th
2 subsets are promoted by GATA-3 transcription factor activation by IL-4 secretion by
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naïve CD4+ T cells. Of additional importance is that cytokines, secreted by a particular Th
subset, are able to further promote the expansion of that subset population while
inhibiting the development of the other Th population (Gutcher and Becher, 2007).
Effector T cell responses need to be controlled after completing its mission of
eradicating pathogens, in order to prevent it from inducing autoimmune conditions
(Beissert et al., 2006). The T regulatory (T regs) cell subtype, are the primary cells
responsible for managing this process. These cells were first described in the early 1970s
as suppressor T cells (Beissert et al., 2006). However, their existence was questioned and
the presence of these cells in the immune system was dismissed (Wickelgren, 2004).
Their presence was revived in the 1990s with an abundance of research in the field
leaving no doubt as to their existence. Since then, there has been continued research on
defining lineage specific markers for these cells, with the front-runners being
CD4+/CD25+ and Fox P3+ T cells. T regs can suppress T cell responses by tolerizing T
cells in certain conditions. It is believed that the control of T cell responses by T regs will
provide clues in the management of numerous immune disorders (Wickelgren, 2004).

Ginseng
In 1994 the United States Congress passed the Dietary Supplement Health and Education
Act to promote consumer access to dietary supplements (Engel and Straus, 2002). This
law defined a new category of food — “dietary supplement” — which would include
herbs and other botanicals, vitamins and minerals, and other substances (Engel and
Straus, 2002). Since the passage of this act, the dietary supplement industry has
experienced considerable growth (Noonan and Patrick Noonan, 2006). However, the
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marketing of these products as food also opened the door for their sales without
standardized test to prove whether they are safe, efficacious or produced under current
good manufacturing processes (CGMP). As a result, on June 25, 2007, the Food and
Drug Administration (FDA) issued guidelines which ensures that dietary supplements are
produced in a quality manner, do not contain contaminants or impurities and are
accurately labeled. While these rules will enable the application of CGMP that provides
some measure of protection for the public, it does not adequately address whether these
products are biologically safe or effective.
Currently, ginseng is one of the most popular dietary supplements, with an annual sale
of over USD 200 million (Yue et al., 2007). Ginseng is a deciduous perennial plant that
belongs to the Araliaceae family. Presently, twelve species of Ginseng have been
identified. Among them, Panax ginseng C. A. Meyer, P. quinquefolium L and P.
notoginseng are the three most well known and scientifically investigated species.
Ginseng is purported to have numerous pharmacological and therapeutic properties. It
affects the central nervous system (CNS), cardiovascular system, endocrine secretion,
immune function, metabolism, and has anti-stress and anti-aging actions. These
properties have been primarily attributed to the ginsenoside components of Ginseng.
However, studies also suggest that phytosterols, peptides, polysaccharides, fatty acids,
polyacetylenes, vitamins and mineral components also contribute to Ginseng’s, biological
effects (Buettner et al., 2006).
Ginseng has been used clinically in China, Korea and Japan for thousands of years
(Radad et al., 2006; Yue et al., 2007). In the 18th century, the West recognized the
medicinal advantages of Ginseng. This subsequently led to a large number of
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Figure 1-4.

Figure 1-4. The chemical structure of ginsenosides. glc = glucosyl (C6H11O6-); rha =
rhamnosyl (C6H11O5-); ara = arabinosyl (C5H9O5-); p = pyran; f = furan. This figure was
obtained from (Yue et al., 2007).
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investigations being conducted on its botany, chemistry, pharmacology and therapeutic
applications (Yue et al., 2007).

Ginsenosides
As previously mentioned, the most prominent and pharmacologically active constituents
of ginseng are the saponin glycosides known as ginsenosides (Yue et al., 2007). Over
thirty ginsenosides have been isolated and characterized from various Ginseng species
(Fig. 1-4) (Buettner et al., 2006). In general, the concentration and types of ginsenosides
present in a Ginseng plant vary widely, depending on the species, age and part of the
plant used, and even the preservation or extraction method (Yue et al., 2007). It is
therefore possible that products containing the same amount of total ginsenosides could
contain different individual ginsenoside compositions and ratios (Buettner et al., 2006).
The variability in ginsenoside content in Ginseng contributes to the heterogeneity of
reported findings in the research of this herbal (Buettner et al., 2006). This is because
different ginsenosides have different pharmacological effects which can sometimes
enhance or antagonize observed medicinal effects depending on their concentrations in a
particular species (Buettner et al., 2006). Ginsenosides are usually classified into three
major categories, namely protopanaxadiols (PPD) (e.g. Rb1, Rb2, Rc, Rd, Rg3, Rh2),
protopanaxatriols (PPT) (e.g. Re, Rf, Rg1, Rg2, Rh1) and the oleanolic acid derivatives
(Yue et al., 2007). These compounds have a steroid-like skeleton consisting of four transrings, with differences from each other being dependent on the type (e.g. glucose,
maltose and fructose), number of sugar moieties and the sites of attachment of the
hydroxyl group (Yue et al., 2007). Ginsenosides are amphipathic in nature with the

20

hydroxyl (-OH) groups allowing both interactions between the polar head of
phospholipid membranes and the β-OH group of cholesterol, and the hydrophobic steroid
backbone interacting with the hydrophobic side chains of fatty acids and cholesterol.
Ginsenosides are thought to exhibit their actions through a number of mechanisms
including signaling through the plasma membrane, cytosol, or even in the nucleus. They
can initiate binding to membrane receptors such as ATPase pumps, ion transporters and
channels, voltage gated channels and G-proteins and subsequently activate associated
downstream signaling cascades (Yue et al., 2007). As they are amphipathic, they can
intercalate into plasma membranes resulting in alterations in membrane fluidity, thereby
triggering a series of cellular responses. Ginsenosides can also potentially bind to a
number of intracellular steroid hormone receptors including glucocorticoid receptor
(GCR), estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR) and
mineral corticorticoid receptor (MR), using their hydrophobic 'steroid-like' backbone
(Fig.1-5) (Yue et al., 2007). This can lead to the regulation of gene transcription by
binding with the specific gene response elements.

Absorption, Distribution and Metabolism
After oral ingestion, ginsenosides pass through the stomach and small intestine and into
the large intestine without decomposition by either gastric juice or liver enzymes (Fig. 16) (Hasegawa, 2004) . However, upon arrival into the large intestines, ginsenosides may
be deglycosylated by colonic bacteria prior to absorption and transit to the circulation.
Studies in rats suggest that the oral bioavailability of the intact ginsenoside is extremely
low, varying from 0.1-18 % depending on the type of ginsenoside tested
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Figure 1-5.

Figure 1-5. Schematic overview of ginsenoside-mediated genomic and non-genomic
pathways. Ginsenosides possess a steroid-like skeleton composed of four trans-rings
with different degrees of glyco-substitution. As ginsenosides are amphipathic in nature
they can exhibit their actions at different cellular locations, such as the plasma
membrane, cytosol and nucleus. Through the non-genomic pathway, (i) they can initiate
their actions by binding with the transmembrane receptors, intercalating into the plasma
membrane resulting in an alteration of membrane fluidity and (ii) binding with steroid
hormone receptors (SHRs) present inside or outside the nucleus. (iii) the ligand-bound
SHRs can translocate into the nucleus, where they regulate gene transcription by binding
with the specific Response Elements (XRE). This is the so-called 'genomic pathway'.
Consequently, the altered gene products can affect the final cellular responses. This
figure was adapted from (Yue et al., 2007).
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Figure 1-6.

Figure 1-6. Metabolic Activation of Ginsenosides.
Putative metabolic pathways of ginsenosides in the body after oral administration.
Ginsenosides are deglycosylated to M1 or M4 by intestinal bacteria. This is followed by
absorption into the blood or mesenteric lymphatics. Although most of M1 is excreted as
bile, some M1 may be esterified with fatty acids at C-3 of the aglycone moiety or C'-6 of
the glucose moiety in the liver. EM1 is not excreted in the small intestine and
accumulates in the liver longer than M1. However, most M4 is esterified with fatty acids
and accumulates in tissues including the liver and lung. This figure was obtained from
(Hasegawa, 2004).
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(Hasegawa, 2004). In the large intestines, colonic bacteria cleave the oligosaccharide
connected to the C-3 or C-20 hydroxyl group of the aglycone stepwise from the terminal
sugar (Hasegawa, 2004).
Thirteen different metabolites might be formed from this process with 20Sprotopanaxadiol 20-O-β-D-glucopyranoside (M1) and 20S-protopanaxatriol (M4) being
the major two (Hasegawa, 2004). Interstitial bacteria responsible for ginsenoside
metabolism include, Prevotella oris, Eubacterium A-44, Bifidobacterium K506,
Bacteroides JY6, and Fusobacterium K-60.
Following absorption from the intestines, metabolites can be further esterified with
fatty acids by the liver. The resultant fatty acid conjugates are still active molecules that
are sustained longer in the body than parental metabolites (Hasegawa, 2004). It is of
importance to note that intestinal bacteria are changeable dependent on host conditions
including diet, health and even stress. Bacterial ginsenoside-hydrolyzing potentials can
differ among humans and experimental mice (Hasegawa, 2004). Therefore, it is possible
that the individual differences in bacterial ginsenoside-hydrolyzing potentials account for
differences in Ginseng efficacy. Additionally, although the absorption, distribution and
metabolism of ginsenosides has been studied in animals and in vitro, knowledge
concerning the systemic availability of ginsenosides and their degradation products in
humans is still vastly limited and is mostly inconclusive (Tawab et al., 2003).

The effects of Ginseng on the immune system
One of the primary uses of Ginseng is to modulate immune function (Kiefer and Pantuso,
2003). Ginsenosides as well as the polysaccharide components of Ginseng have been
shown to reduce inflammation in various experimental models (Ahn et al., 2006).
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Numerous experiments have demonstrated decreased inflammatory mediator
production by activated innate immune cells after Ginseng treatment. This includes
decreased cytokine production by macrophages and mast cells (Hofseth and Wargovich,
2007; Kim et al., 2007). In addition, decreased expression and production of inducible
inflammatory enzymes such as cycooxygenase-2 (COX-2) and inducible nitric oxide
synthase (iNOS) in innate immune cells were demonstrated in a number of studies (Kim
et al., 2007).
Limited information exists describing the effects of Ginseng or its derivatives on DCs.
In the one study published on human DCs, there was an increase in maturation signals
after treatment with M1 and M4 metabolites of Ginseng (Takei et al., 2004). However,
there was no information presented about the effects of the non-metabolized components
which retain biologic activity.
The effects of Ginseng and its derivatives on the adaptive immune system have also
been widely studied in various experimental models. In many of these studies, Ginseng is
touted as possessing adjuvant effects, as there is an enhancement of the humoral response
in animals immunized with ovalbumin and dosed with Ginseng (Qin et al., 2006; Sun et
al., 2005; Sun et al., 2007; Yang et al., 2007b). This response was measured by analysis
of antigen-specific antibody titers. In short-term (10-50 µg on days 1 and 15) treatment of
immunized mice with Ginseng/ginsenosides there was an enhanced Th1 and Th2
cytokine production, while long-term (30 consecutive days with 2 g/kg of a 50% ethanol
extract of ginseng root) exposure resulted in decreased amounts of cytokines (Liou et al.,
2005; Yang et al., 2007a; Yu et al., 2004). Interestingly, in another experiment
determining the actions of individual ginsenoside on T cell proliferation induced by
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various T cell mitogens, ginsenoside Rb1 and Re enhanced proliferation while Rb2
inhibited proliferation in vitro (Cho et al., 2002b). This suggests that ginsenosides can
differentially regulate lymphocyte proliferation.
The effects of Ginseng and its components can therefore be described as being
diverse. Properties of Ginseng are dependent on the branch of immunity studied, with
most studies suggesting decreased inflammatory responses and modulation of adaptive
immunity. Additionally, Ginseng possesses different ginsenoside and polysaccharide
components that vary with season, time of harvest and location of growth. The
composition of these components in Ginseng species may dictate the observed effects on
immunity.

Exploiting the effects of notoginseng on APCs for immunotherapy
The information described in the previous section demonstrates that Ginseng
possesses immunomodulatory capability. Moreover, as described previously, many of the
effects of Ginseng on immune cells occur through the action of ginsenosides. Of the three
most popular Ginseng species, the highest concentration of ginsenosides is present in
Panax notoginseng. Therefore, this herb is ideal for studying the effects of Ginseng
extracts on immune cells.
As previously mentioned, APCs are among the first cells present at the site of an
infection, releasing cytokines and other inflammatory proteins to combat pathogens. In
addition, APCs are initiators and modulators of the adaptive immune response
(Banchereau and Steinman, 1998; Medzhitov and Janeway, 1998). They are important
intermediaries between microorganisms and the control of the immune system (Lee and
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Iwasaki, 2007; Steinman, 2001). For this reason, regulation of APCs should significantly
influence both innate and adaptive immunity.
Of the three types of APCs described above, macrophages and DCs are most likely to
elicit an adaptive immune response (St Clair et al., 2007). This is because they reside in
areas more likely to be exposed to antigens where they can phagocytose pathogens. As a
result of their superior antigen presenting capabilities, DCs have received the most
attention as activators of T cells. Recently, research efforts have been focused on ways to
manipulate DCs to control immune function. These studies take advantage of the basic
properties of DCs and how they can manipulate them to treat or cure diseases. This
includes loading DCs with a particular antigen, as in the case for vaccines against various
pathogens such as HIV or even cancer cells. In this case, DCs will direct adaptive
immune cells to elicit a response against pathogens or cells bearing this antigen.
Alternatively, if suppression of the immune system is desired as in the case of
inflammatory or autoimmune diseases, DCs can be manipulated to decrease their innate
and adaptive immune functions. This may include reducing TLR activation, decreasing
the production of pro-inflammatory cytokines, increasing the production of antiinflammatory

cytokines,

downregulating accessory/costimulatory molecules and

suppression of T cell responses (Morel et al., 2003).
Various strategies have been used, including treatment with pharmaceutical nonsteroidal and steroidal agents, to manipulate APC activity. However, as numerous people
suffer from inflammatory diseases, research continues on finding agents for modulating
the immune system as a remedy for these ailments.

27

Panax notoginseng has been demonstrated to have numerous effects on the immune
system, including decreasing inflammation. However, further research is necessary to
elucidate the effects of this herbal on both innate and adaptive immunity. As APCs play a
major role in coordinating events in both innate and adaptive immune function, studying
the effects of notoginseng on the fate and function of APCs should provide benefit to the
fields of immunopharmacognosy and biomedical science.

Hypothesis
Panax notoginseng alters APC fate and function by decreasing activation molecule
expression and inflammatory mediator production by macrophages and DCs. To address
this hypothesis, several studies were performed focusing on the following specific Aims:

Aim 1. (Chapter 2)
To determine if Panax notoginseng attenuates LPS-induced pro-inflammatory mediators
in macrophages using RAW264.7 cells.

Aim 2. (Chapter 3)
To investigate whether Panax notoginseng decreases APC activation induced by selected
Toll-Like receptor ligands in murine DC2.4 dendritic cells in vitro.

Aim 3. (Chapter 4)
To evaluate the effects of Panax notoginseng on innate and adaptive immune fate and
function of primary APCs in vitro and in vivo.
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In addition to these three specific Aims, studies were also conducted to determine
whether Panax notoginseng could be used as a therapeutic agent to treat diseases with an
inflammatory component. In our first set of studies, the general toxicity of ginseng was
investigated with specific attention to the immune system. The second study was based
on our previous results on the effects of notoginseng on decreased antigen uptake and
inflammatory mediator production by APCs. In these experiments we assessed the effects
of notoginseng on uptake of acetylated LDL (ac-LDL) by BMDCs. The aims for these
two studies are described below.

Aim 4. (Chapter 5)
To determine the immunotoxicological effects of Panax notoginseng in vivo in ova
immunized Balb/c mice.

Aim 5. (Chapter 6)
To investigate whether Panax notoginseng can reduce uptake of ac-LDL by BMDCs.

Finally, Chapter 7 will include a summary of the results presented in this dissertation and
the significance and long-term implications of this study. This chapter will also provide
insight on the future directions for continued research on the effects of Panax
notoginseng on immune cells.
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Abstract
Herbals or dietary supplements are not regulated as drugs by the United States Food and
Drug Administration (USFDA) although many may have associated therapeutic effects
and toxicities. Therefore, the immunomodulatory effects of the herbal extract Panax
notoginseng on cultured macrophages (RAW264.7 cells) were investigated to address
potential therapeutic or toxic effects. Cells were stimulated with LPS (1 µg/ml) and
treated with notoginseng at 5, 25 and 50 µg/ml. Notoginseng inhibited the LPS-induced
production of TNF-α and IL-6 by the cultured macrophages in a concentration-dependent
manner. The expression of COX-2 and IL-1β mRNA was also attenuated by notoginseng.
TNF-α production was inhibited in samples treated with notoginseng 24 hours before, or
at the same time as LPS stimulation, but not in samples treated 8 hours after LPS
stimulation. Notoginseng reduced expression of the accessory molecules CD40 and
CD86 on the RAW264.7 cells while CD14 and TLR4 expression remained unaffected.
Furthermore, Rb1 and Rg1 ginsenosides also inhibited macrophage production of TNF-α,
but to a lesser extent than did the whole notoginseng extract. Collectively, these results
indicate that notoginseng inhibits LPS-induced activation of RAW264.7 macrophages
and demonstrates that notoginseng possesses anti-inflammatory and immunosuppressive
properties in vitro.

Keywords: Panax notoginseng; Ginsenosides; RAW264.7; Macrophages; Inflammation.
Abbreviations: LPS, lipopolysaccharide; TNF-α, tumor necrosis factor-alpha; IL-1β,
Interleukin-1 beta; IL-6, Interleukin-6; COX-2, cyclooxygenase-2.

34

Introduction
Over the last decade there has been a steady increase in the use of herbal and dietary
supplements. The rise in popularity of natural products may be attributed to more
aggressive sales tactics, enhanced Internet accessibility and dissatisfaction with
conventional medicines (Barnes et al., 2004). There also exists a misconception that
“natural” is synonymous with safe despite the fact that herbal products can cause medical
problems if not taken correctly or if taken in excessive amounts (Klepser Bailey and
Micheal, 1999). The United States Food and Drug Administration (USFDA) does not
classify natural products as drugs despite associations with both therapeutic effects and
toxicities. This means that, unlike conventional drugs, natural products are not required to
meet rigorous standards to demonstrate safety, efficacy and mechanisms of action.
Recent evidence demonstrates that natural products have the capacity to interact with
conventional drugs via modulation of various xenobiotic metabolizing enzymes such as
CYP2C9 and CY3A4 (He and Edeki, 2004). The rise in natural product usage and the
potential for adverse or advantageous reactions has led to increased attention to their
potential safety and efficacy.
Among these widely used natural products, ginseng was the second most frequently
purchased herbal by the US adult population in 2002 (Barnes et al., 2004). Over thirteen
species of ginseng have been identified, including Panax notoginseng (Burk.) F.H. Chen
ex C.Y. Wu & K.M. Feng (Yun, 2001). The biologically active compounds of ginseng
species are thought to be the saponins of which the ginsenosides Rb1, Rg1, Re1, Rh1 and
the notoginsenoside R1 are considered to be the major components of Panax notoginseng
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(Li et al., 2005; Yun, 2001). The biological activity of Panax notoginseng is similar to the
more widely known Panax ginseng plant, with differences in activity associated with
higher levels of ginsenosides in the notoginseng species (Chuang et al., 1995; Zhu et al.,
2004). Ginseng is highly regarded in China for its therapeutic ability to stop
hemorrhages, influence circulation, act as a tonic, induce variable effects on systemic
blood pressure, and generate analgesic and anti-inflammatory effects (Xu et al., 2003).
Notoginseng’s cardiovascular effects occur via inhibition of calcium entry through
receptor-mediated calcium channels without affecting voltage gated calcium channels or
intracellular calcium release (Kwan, 1995a). The ginsenosides Rb1 and Rg1 also have
stimulatory effects on the central nervous system. They can improve memory, learning
and confer neuroprotection in some instances (Attele et al., 1999).
The immunomodulatory effects of notoginseng have not been fully characterized.
Several studies have described the effects of ginseng and ginsenosides on the immune
system, but specific mechanisms of action have yet to be identified. Noted immunologic
effects include anti-allergic and anti-inflammatory activities of Rh1 (Park et al., 2004), a
reduction in TNF-α levels by Rb1 (Smolinski and Pestka, 2003a), an increase in both
humoral and cell-mediated immune responses by Rg1 (Kwan, 1995a), and a decrease in
phospholipase 2 activity and neutrophil numbers by P. notoginseng extract (Li and Chu,
1999).
Macrophages are immune cells usually dispersed throughout the body. They are
particularly important in innate immunity as they are among the first cells responding to
microbial infection. They can kill pathogens directly by phagocytosis and indirectly via
the secretion of pro-inflammatory cytokines such as the TNF-α, IL-1β, and IL-6. These
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cytokines lead to a variety of responses including the induction of cyclooxygenase-2
(COX-2) expression (Turini and DuBois, 2002), increased expression of adhesion
molecules on vascular endothelial cells (Luscinskas and Gimbrone, 1996), the induction
of acute–phase response proteins by the liver (Diehl and Rincon, 2002), and the
production of colony stimulating factors by activated endothelial cells which induce
hematopoesis (Watowhich, 1996).
Macrophages also serve an important role as an interface between innate and
adaptive immunity. They are responsible for processes such as antigen processing and
presentation to antigen-specific T cells. Following activation, macrophages can modulate
expression of accessory molecules such as CD14 and TLR4 that facilitate LPS uptake
and signaling (Dunzendrfer et al., 2004). Activation also induces costimulatory
molecules such as CD40 and CD86 that promote sustained stimulatory interactions with
T cells and the generation of adaptive immunity (Grewal and Flavell, 1998; Lenschow et
al., 1996). Any compound capable of modulating macrophage activation and/or function
holds great promise for use in the treatment of chronic inflammatory diseases such as
asthma, atherosclerosis and rheumatoid arthritis.
In this study, we hypothesized that notoginseng would reduce the production of proinflammatory mediators by LPS-stimulated macrophages. To test this hypothesis, the
production of the inflammatory mediators, TNF-α and IL-6, as well as the expression of
IL-1β and COX-2 mRNA were evaluated in RAW264.7 murine macrophages treated
with LPS and notoginseng. The effect of notoginseng on the expression of accessory
molecules CD14, TLR4, CD86 and CD40 on RAW264.7 cells was also studied. Further
studies examined the effects of the purified ginsenosides, Rb1 and Rg1, on LPS-induced
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TNF-α and IL-6 production. Our results confirm and extend previous findings of the
immunomodulatory effects of notoginseng. Experiments in this paper demonstrate for the
first time that these effects are dependent on the duration of treatment, can alter proinflammatory molecule expression at the mRNA level, and can modulate important
accessory molecules commonly expressed on macrophages. Moreover, these results
demonstrate that notoginseng attenuates the production of several pro-inflammatory
mediators by macrophages following in vitro stimulation by LPS.

Materials and Methods
Chemicals
Noto-GTM extracts from the plant Panax notoginseng (Burk.) F.H. Chen ex C.Y. Wu &
K.M. Feng were kindly supplied by Technical Sourcing International, Inc. (TSI)
(Missoula, MT). Notoginseng was extracted from the root of the plant using ethanol and
standardized to contain Rb1 and Rg1 ginsenosides at 35 and 34% of the whole extract,
respectively. The quantification of Rb1 and Rg1 in the notoginseng extract was
determined by high-performance liquid chromatography analysis by TSI. Documentation
by TSI also showed no detectable levels of Escherichia coli (E. coli) or Salmonella
enterica in the notoginseng preparation (unpublished data). Certification of analyses were
approved by Xia Ronglong (QA manager TSI). The extract was dissolved in complete
media (see below) or culture-grade DMSO (Sigma-Aldrich, St. Louis, MO) and
subsequently sterile-filtered through a 0.22 µM Millipore membrane. The purified
ginsenosides Rb1 and Rg1 were purchased from Indofine Chemical Company, Inc.
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(Hillsborough, NJ). Lipopolysaccharide (LPS) from E. coli (055:B5) was obtained from
Sigma-Aldrich.

Cell Culture
RAW264.7 cells were obtained from ATCC (Manassas, VA). Cells were grown in RPMI
(GibcoBRL, Grand Island, N.Y), supplemented with 10% FBS (Hyclone, Logan, UT), 50
µM mercaptoethanol, 20 mM HEPES, 10 mM sodium pyruvate and 50 µg/ml gentamicin
(GibcoBRL, Grand Island, N.Y). RAW264.7 cells were maintained via weekly passage
and cells were utilized for experimentation at 60-80% confluency.

Cell Activation and Treatment
RAW264.7 cells (5 X 105 cells per well) were incubated overnight at 37 0C and 5% CO2
in 6-well plates to facilitate attachment and spreading before experimentation. Cells were
then stimulated with 1 µg/ml LPS and treated with 0, 5, 25 or 50 µg/ml notoginseng or
Rb1 and Rg1 ginsenosides at concentrations equivalent to that in 50 µg/ml notoginseng.
After an additional 24 hours supernatants were collected for evaluation by ELISA and
cells harvested for RT-PCR and FACS analysis.

Cytokine Assays
The inhibitory effects of notoginseng on the production of IL-6 and TNF-α were
measured by enzyme-linked immunosorbent assay (ELISA) using supernatants collected
from treated cells. Samples were analyzed per the manufacturer’s recommendations with
mouse cytokine-specific BD OptEIA ELISA kits (BD PharMingen, San Diego, CA).
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RT-PCR
RT-PCR for the detection of IL-1β and COX-2 mRNA was performed as previously
described (Shepherd et al., 2001). Briefly, total RNA was isolated using Trizol and
reverse transcribed into cDNA. COX-2 and IL-1β transcripts were identified using
specific forward and reverse primers as per manufacturer’s instructions (Clonetech, Palo
Alto, CA). β-2 microglobulin expression was included as an internal, housekeeping gene
control. Ethidium bromide-stained reaction products were separated by electrophoresis on
a 2% agarose gel in TBE and visualized by UV transillumination. Images were captured
by a Kodak EDAS 290 camera system (Kodak, Rochester, NY).
The primers used in these experiments were designed to span introns thereby allowing
differentiation between amplified genomic DNA and cDNA PCR products. Primers
sequences used were β-2 microglobulin 5′ ATGGCTCGCTCGGTGACCCT and 3′
TCATGATGCTTGATCACATG, IL-1β 5′ ATGGCAACTGTTCCTGAACTCAACT
and

3′

CAGGACAGGTATAGATTCTTTCCTTT

and

COX-2

5′

AACACAGCTACGAAAACC and 3′ CACAGTATGATGTAACAGTCC.

Flow cytometry
The detection of accessory molecule expression on RAW264.7 cells by fluorescent
activated cell sorting (FACS) analysis was performed as previously described (Shepherd
et al., 2001). Briefly, RAW264.7 cells were harvested and washed with PAB (1% bovine
serum albumin and 0.1% sodium azide in PBS). Cells were blocked with 50 µl of 600
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µg/ml purified rat and/or hamster IgG (Jackson ImmunoResearch, West Grove, PA) for
10 minutes to inhibit non-specific staining. Flurochrome-conjugated antibodies to mouse
were then added at 1 µg/ml concentrations for an additional 10 minutes. The antibodies
used in these experiments were CD86-APC, CD40-PE, TLR4-PE, CD14-FITC, and their
corresponding isotype controls (BDPharmingen, San Diego, CA, except for the antiTLR4 eBiosciences, San Diego, CA). One hundred thousand viable cells per treatment
(as determined by light scatter profiles and propidium iodide staining) were analyzed
using a BD FACSAria flow cytometer and FACSDiva software (BD Biosciences, San
Jose, CA).

Statistics
All statistical analyses were performed using GraphPad Prism 4.0a for the Macintosh
(GraphPad Software, San Diego, CA). Data signify the mean +/- of 3 samples and are
representative of 3 independent experiments. Differences between two means were
analyzed by Student’s t-test. Data sets with multiple comparisons were evaluated by oneway analysis of variance (ANOVA) with Dunnett's post test. Values of p < 0.05 were
determined to be significant.

Results
Notoginseng suppresses the LPS-induced production of TNF-α and IL-6 by RAW264.7
cells
RAW264.7 cells are an immortalized monocyte/macrophage murine cell line that has
been used extensively to evaluate monocyte and macrophage fate and function in vitro.
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To evaluate the potential effects of notoginseng on macrophage function, RAW264.7
cells were stimulated with 1µg/ml LPS and concomitantly treated with notoginseng.
Unstimulated RAW264.7 cells secrete a basal level of TNF-α but barely detectable
amounts of IL-6 (Figs. 2-1A and 2-1B, respectively). At the highest concentration tested,
notoginseng did not evoke TNF-α or IL-6 release in the absence of LPS stimulation. The
addition of LPS resulted in a 9-fold and 120-fold increase in TNF-α and IL-6 protein
levels, respectively. Notoginseng significantly inhibited the production of both TNF-α
and IL-6 in a concentration-dependent manner.

At the highest concentration of

notoginseng tested, TNF-α production was reduced approximately 3-fold while IL-6
production was reduced 7-fold. Importantly, no cytotoxicity was observed at any of the
concentrations of notoginseng examined, as assessed by trypan blue exclusion (data not
shown).

Also, no significant differences were observed in cell recoveries between

notoginseng- and control-treated cells.

COX-2 and IL-1β mRNA levels are decreased in LPS-stimulated RAW264.7 cells
following exposure to notoginseng
Because of the prominent role of COX-2 and IL-1β in the inflammatory response, the
potential for notoginseng to alter the expression of these mediators was investigated.
COX-2 and IL-1β mRNA levels in RAW264.7 cells were evaluated by RT-PCR. The
mRNA expression of the housekeeping gene β-2 microglobulin was used to normalize
samples. Untreated RAW264.7 cells expressed detectable levels of both COX-2 and IL1β mRNA that increased following LPS stimulation (Fig. 2-2). Notoginseng inhibited
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Figure 2-1

A.

B.

Figure 2-1. Notoginseng inhibits the LPS-induced TNF-α and IL-6 production by
RAW 264.7 cells. Cells were treated simultaneously with 1µg/ml LPS and 5, 25 or 50
µg/ml of notoginseng. Supernatants were collected after 24 hours and assayed for TNF-α
(A) and IL-6 (B) production as described in the Materials and Methods. Data represents
mean +/- SEM of 3 samples. # indicates significant difference between stimulated and
unstimulated cells; * indicates significant differences between the LPS-stimulated
control- and notoginseng-treated samples (p < 0.05). Data are representative of 3
independent experiments.
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Figure 2-2

UNTREATED
Untreated

LPS

NOTOGINSENG

50

50

25

5

No LPS

LPS

LPS

LPS

COX-2

IL-1β

β2
microglobulin

Figure 2-2. Notoginseng decreases COX-2 and IL-1β mRNA levels following LPS
activation of cultured macrophages. RAW 264.7 cells were treated simultaneously with
1µg/ml LPS and 5, 25 or 50 µg/ml of notoginseng for 24 hours. Cells were harvested, and
mRNA extracted and transcribed into cDNA. Expression levels of COX-2 and IL-1β
mRNA were measured by RT-PCR and visualized by ethidium bromide staining of a 2%
agarose gel. β-2 microglobulin (β2) was included as a housekeeping gene to normalize
all samples. Data are representative of 3 separate experiments.
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LPS-induced IL-1β mRNA expression in a concentration-dependent manner and reduced
the expression of COX-2 mRNA in LPS-stimulated macrophages at the higher
concentrations examined (Fig. 2-2). Interestingly, mRNA expression levels of both proinflammatory genes were decreased in RAW264.7 cells that were not stimulated with
LPS, but treated with the highest concentration of notoginseng only.

Notoginseng selectively modulates the expression of key accessory molecules
The expression levels of accessory/costimulatory molecules on macrophages can dually
affect their inflammatory responsiveness and capacity to function as antigen presenting
cells. To determine if notoginseng modulates accessory molecule expression on activated
macrophages, RAW264.7 cells were treated concomitantly with LPS and 50 µg/ml of
notoginseng and the fluorescence intensity of CD40, CD86, CD14 and TLR4 measured
by flow cytometry. Only the highest concentration of notoginseng was evaluated in this
experiment since significant inhibition of other inflammatory mediators had been
demonstrated at this concentration (Figs. 2-1 and 2-2). Stimulation of RAW264.7 cells
with LPS increased the expression of CD40, CD86 and CD14 (Table 2-1). Conversely,
LPS treatment results in down-regulation of TLR4 expression on RAW264.7 cells as has
been previously reported (Akashi et al., 2000). Notoginseng decreased the LPS-induced
expression of CD40 by almost 20% (Fig. 2-3A) and CD86 by 30% (Fig. 2-3B) on
RAW264.7 cells. In contrast, cell surface expression of TLR4 and CD14 remained
unchanged following notoginseng exposure (Table 2-1).
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Table 2-1. Notoginseng differentially affects the expression of LPS-induced
accessory molecules.

CD40 MCFb

CD86 MCF

CD14 MCF

TLR4 MCF

Untreateda

320 ± 16

538 ± 25

117 ± 9

354 ± 25

+ LPS

513 ± 21#c

1060 ± 25#

192 ± 8#

252 ± 23#

+ LPS
NOTOGINSENG

429 ± 31#*

737 ± 35#*

194 ± 4#

244 ± 21#

a

RAW264.7 cells were either unstimulated or stimulated with LPS (1µg/ml). Some of

the LPS-treated samples were concomitantly treated with notoginseng (50 µg/ml) for 24
hours.
b
c

Mean Channel Fluorescence (MCF) was determined by flow cytometry.
Data shown are representative of four independent experiments. Error bars indicate

mean ± SEM; #, p < 0.05 for the comparison of unstimulated and LPS-activated cells; *,
p < 0.05 for the comparison of LPS-stimulated cells treated with notoginseng or left
untreated.
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Figure 2-3

Number

A.

CD40

Number

B.

CD86
Figure 2-3. Notoginseng treatment of RAW264.7 cells selectively modulates cell
surface expression of accessory molecules. RAW264.7 cells were unstimulated (white
histogram), stimulated with LPS

(black histogram) or stimulated with LPS and

concomitantly treated with 50 µg/ml notoginseng (grey histogram) for 24 hours.
Representative histograms demonstrating the cell surface expression of CD40 (A) and
CD86 expression (B) on viable RAW264.7 cells receiving various treatments were
determined by FACS analysis.

Values in histograms correspond to specific Mean

Channel Fluorescence (MCF) values for each treatment. Data are representative of 3
independent experiments.
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TNF-α production is affected by notoginseng in a time-dependent manner
To assess if the duration of notoginseng exposure results in differential effects on TNF-α
production, RAW264.7 cells were either pretreated with notoginseng for 24 hours prior to
LPS addition (-24 hr timepoint), treated with notoginseng and LPS simultaneously (0 hr),
or treated with notoginseng 8 hours (+8 hrs) after LPS addition. All samples were
collected 24 hours after LPS stimulation. Consistent with the results presented in Fig. 21, concomitant treatment of RAW264.7 macrophages with LPS and notoginseng
significantly suppressed the production of TNF-α after 24 hours of culture by more than
50% (Fig. 2-4). Pretreatment of RAW264.7 cells with notoginseng for 24 hours resulted
in a 17% decrease in TNF-α levels. It should be noted that for these cultures, the herbal
extract was not removed from the medium after 24 hours but remained for the entire
culture period of 48 hours. In contrast, delaying the addition of notoginseng by 8 hours
relative to LPS treatment, resulted in no significant reduction of TNF-α although a trend
towards lesser levels was observed.

The purified ginsenosides Rb1 and Rg1 modulate the production of TNF-α by RAW264.7
cells
The whole notoginseng extract used in the preceding experiments is comprised of several
ginsenosides although primarily of Rb1 (35%) and Rg1 (34%). Because ginsenosides are
believed to comprise much of the biological activity of notoginseng, we sought to define
the potential inhibitory effects of the purified ginsenosides Rb1 and Rg1 on LPS-induced
TNF-α production by RAW 264.7 cells. To more closely mimic the approximate
concentration of ginsenosides present in the whole extract, Rb1 and Rg1 were
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Figure 2-4

Figure 2-4. Variable notoginseng treatment affects the LPS-induced production of
TNF-α by RAW 264.7 cells. Cells were treated with notoginseng at three different
timepoints: –24 hours, 0 hours and 8 hours, relative to LPS stimulation. Supernatants
were collected 24 hours after LPS addition and TNF-α levels measured by ELISA. Data
represents mean +/- SEM of 3 samples. # Indicates significant differences between
stimulated and unstimulated cells; * indicates significant differences between LPSstimulated controls and LPS-stimulated, notoginseng-treated samples (p < 0.05). Data are
representative of 3 separate experiments.
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standardized to approximate concentrations found in 50 µg/ml of the intact notoginseng
extract. Following LPS activation of RAW264.7 cells, both Rb1 and Rg1 and a
combination of the Rb1/Rg1 purified compounds significantly inhibited TNF-α
production (Fig. 2-5A). However, neither ginsenoside alone or in combination attenuated
TNF-α production to the extent that was observed following exposure to the whole
notoginseng extract. In addition, the whole notoginseng extract and ginsenoside Rg1
caused significant inhibition of LPS-induced IL-6 by RAW264.7 cells (76% and 24% of
LPS-stimulated controls, respectively). Conversely, no significant suppression was
detected after the addition of Rb1 to these cultures (Fig. 2-5B).

Discussion and conclusion
In the current study, the potential for notoginseng to decrease the LPS-induced
production or expression of cytokines, TNF-α, IL-6, and IL-1β, was tested because of
their significance in inflammatory conditions. The production of these inflammatory
molecules by RAW264.7 cells can be induced in response to LPS stimulation (Beutler,
2003; Rice and Bernard, 2005). TNF-α is primarily produced by monocytes,
macrophages and T-cells (Bondeson, 1997) and has various pro-inflammatory effects on
many cell types. It is a potent activator of macrophages, can stimulate the production or
expression of IL-1β, IL-6, prostaglandin E2, collagenase, type I and III collagens,
adhesion molecules and is a growth factor for both B and T lymphocytes (Bondeson,
1997). Both TNF-α and IL-1β can lead to cartilage destruction and bone resorption and
are important cytokines in chronic inflammatory diseases such as rheumatoid arthritis
(RA) (Bondeson, 1997; Dayer, 2004). IL-6 has also been shown to be important in a
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Figure 2-5

A.

B.

TNF-α

IL-6

Figure 2-5. The production of TNF-α and IL-6 is selectively suppressed by the
whole notoginseng extract and purified ginsenosides. LPS-stimulated cells were
treated with 50 µg/ml whole notoginseng extract or purified Rb1 and/or Rg1 compounds.
Supernatants were collected after 24 hours and assayed for TNF-α and IL-6 production
by ELISA. Data represents mean +/- SEM of 3 samples. Statistically significant
differences (p < 0.05) between treatment groups are indicated by different letters. Data
are representative of 3 independent experiments.
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variety of inflammatory conditions and is particularly important in the production of
acute phase proteins (Diehl and Rincon, 2002). Although the present study models
predominately an acute inflammatory condition, our results provide valuable information
variety of inflammatory conditions and is particularly important in the production of on
the effects of notoginseng on macrophages, cells critical in the process of chronic
inflammation (Lefkowitz et al., 1995). The results presented herein show that
notoginseng can decrease the LPS induced production of TNF-α and IL-6 and reduce the
mRNA expression of IL-1β and COX-2 in LPS-stimulated RAW264.7 cells (Figs. 2-1
and 2-2). Cyclooxygenase is a key enzyme involved in the conversion of arachidonic acid
into prostaglandins (Turini and DuBois, 2002). It has been demonstrated to be a critical
pro-inflammatory enzyme contributing to the development of many chronic
inflammatory diseases such as cardiovascular disease, cancer and RA (Rocca and
FitzGerald, 2002). IL-1β is a cytokine that is produced early in the generation of an
inflammatory response (Stylianou and Saklatvala, 1998). It is produced in increasing
amounts in diseases such as RA and atherosclerosis (Andreakos et al., 2004a; Bondeson,
1997). Our results demonstrate that notoginseng effectively inhibits the generation of
cytokines and enzymes in this monocyte/macrophage cell line that are paramount in the
generation of an inflammatory response.
In addition to the effects on cytokines production, notoginseng also significantly
affects the expression of key accessory molecules expressed on macrophages. Bacterial
products

are

potent

inducers

of

many

pro-inflammatory

genes

including

accessory/costimulatory molecules such as CD40 and CD86. CD40 and CD86
subsequently promote sustained interactions between APCs and T cells (Grewal and
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Flavell, 1998). When stimulated with LPS, the cell surface expression of CD86 and
CD40 is increased on RAW264.7 cells (Fig. 3 and Table 1). The upregulation of these
molecules is typically observed during the course of an inflammatory response and
functions to facilitate the recruitment and activation of leukocytes (Grewal and Flavell,
1998; Lenschow et al., 1996; Li and Stark, 2002). Notoginseng effectively decreased the
expression of CD40 and CD86 molecules (Fig. 3). Because CD40 and CD86 are required
for productive interactions between T cells and antigen presenting cells, decreasing their
expression would be expected to attenuate conditions such as chronic inflammatory
disease and autoimmunity (Lenschow et al., 1996; Quezida et al., 2004). In our
experiments, LPS was used as the prototypical inflammatory stimulus because of its
ability to initiate a range of pro-inflammatory mediators (Abreu and Arditi, 2004). LPS
signaling occurs when LPS binding protein catalyzes the transfer of LPS to membrane or
soluble CD14, which then mediates recognition of LPS via TLR4 signaling (Dunzendrfer
et al., 2004). LPS (as well as TNF-α and IL-1β) is an effective activator of NF-κB
(Hanada and Yoshimura, 2002; Karin and Ben-Neriah, 2000a). NF-κB activation induces
the expression of many inflammatory cytokine genes (including TNF-α and IL-1β) and
accessory molecules. In our studies, notoginseng did not affect the expression of TLR4
or CD14 on RAW264.7 cells suggesting that this herbal extract does not decrease LPS
uptake or TLR 4 signaling in these cells. However, although TLR4 and CD14 expression
was unaffected by notoginseng, LPS signaling could potentially be interrupted in its
downstream signaling pathway as has been previously reported (Lee et al., 2002). In
these studies, disruption of NF-κB activation was demonstrated in both mouse skin cells
and the human pro-myelomonocytic cell line, HL-60, by purified ginsenosides (Keum et
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al., 2003a; Lee et al., 2002).

Furthermore, Oh et al. recently reported that 20(S)-

protopanaxatriol, a ginsenoside metabolite, inhibits iNOS and COX-2 expression via the
inactivation of NF-κB in LPS-stimulated RAW264.7 cells (Oh et al., 2004b). Currently,
studies in our laboratory are underway to further characterize the effects of notoginseng
on the activation of NF-κB.
Varying the duration of notoginseng exposure results in differential effects on the
inflammatory responsiveness of our cultured macrophages. In studying the time–
dependent effects of notoginseng on TNF-α production, a trend was observed towards
decreasing LPS-induced production of TNF-α by cells stimulated 8 hours prior to
notoginseng addition. However, significant suppression of this cytokine was only noted
for both the pretreated and concomitant-treated samples (Fig. 2-4). Similar results in our
laboratory have also been observed with the dendritic cell line, DC2.4 (manuscript in
preparation). Reduced effects following delayed notoginseng treatment may be attributed
to an inability of notoginseng to disrupt LPS-stimulated signaling cascades following an
initial activation period as notoginseng may affect initial events in the activation of
RAW264.7 cells. Alternatively, LPS signaling may also reduce the uptake of notoginseng
into cells ultimately decreasing its effectiveness. Thus, it is possible that notoginseng and
LPS may bind to a similar receptor, thereby antagonizing the uptake of the other, if not
added concurrently. This possibility is currently being investigated in our laboratory.
Ginsenosides are believed to be the primary bioactive compounds in notoginseng.
Ginsenoside composition of plants can vary widely depending on factors such as time of
harvest, location and seasonal variations (Lenschow et al., 1996). These parameters can
result in the “yin and yang” in ginseng with various extracts containing significantly
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different activities based on variable ginsenoside profiles (Sengupta et al., 2004).
Therefore, from a clinical perspective it is important to determine if a particular
ginsenoside accounted for the bioactivity of notoginseng. To address this possibility,
purified samples of ginsenosides Rb1 and Rg1 were obtained and their concentration
matched to that present in our whole notoginseng extract. Although these purified
ginsenosides suppressed TNF-α production, the degree of suppression was not as great as
that observed in our original notoginseng samples even when both ginsenosides were
combined (Fig. 2-5). This result could be because although Rb1 and Rg1 accounted for
approximately 70% of our extract, the ginsenoside Re1 and notoginsenoside R1 (each
comprising approximately 4% of notoginseng) may also be contributing to the activity of
the whole extract. Indeed, studies have shown that notoginsenoside R1 can significantly
antagonize the endotoxin-induced activation of endothelial cells in vitro and endotoxininduced lethality in mice (Zhang et al., 1997). Furthermore, our whole notoginseng
extract was obtained from a different commercial source than our purified ginsenosides.
Thus, even if these compounds are similar in concentration, stereoisomerism may still
exist. Stereoisomerism of natural and synthetic compounds has been shown to contribute
to different activities in vivo and in vitro (Mullenheim et al., 2001; Smith et al., 2005). In
vitro studies with different enantiomers of lipoic acid showed that the S isomer had more
activity than the R isomer. Similar mechanisms could explain the reduced suppressive
effects observed when the RAW264.7 cells were treated with the purified ginsenoside
compounds but not the whole extract of notoginseng.
In conclusion, the current study demonstrated that notoginseng treatment of
RAW264.7 cells results in a decreased production of the inflammatory cytokines TNF-α

55

and IL-6, mRNA expression of COX-2 and IL-1β, and cell surface expression of CD40
and CD86 following LPS stimulation. These results establish that notoginseng has potent
anti-inflammatory effects and may hold great promise for use in the treatment of acute
and chronic inflammatory diseases in humans.
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Abstract
Dendritic cells (DCs) play a central role in the regulation of both innate and adaptive
immune responses. The medicinal herb, Panax notoginseng, has been shown to attenuate
the production of pro-inflammatory mediators by innate immune cells. Given the
importance of DCs in immunity, we investigated the potential for notoginseng extracts to
modulate Toll-like receptor (TLR) ligand-induced activation of cultured DC2.4 cells.
Following stimulation with LPS, CpG or poly(I:C) and treatment with 0-50 µg/ml
notoginseng extract for 24 hours, DCs were evaluated for various phenotypic and
functional readouts. Notoginseng reduced the LPS-, CpG- and poly(I:C)-induced
production of TNF-α by DC2.4 cells. Also, IL-6 production by notoginseng-treated cells
stimulated with LPS and CpG but not poly(I;C) was reduced when compared to controls.
TLR ligand-induced CD40 expression was attenuated by notoginseng. In contrast,
notoginseng decreased CD86 levels on DCs activated with LPS and poly(I:C) but not
CpG. Inhibition of TNF-α production was time-dependent in LPS-stimulated cells,
occurring only with pretreatment or concurrent treatment of notoginseng but not after
delayed addition of the herbal extract. Additionally, ginsenoside Rg1 more effectively
inhibited LPS-stimulated cytokine production by DC2.4 cells than ginsenoside Rb1.
Taken together, these results demonstrate that notoginseng inhibits the production of
specific inflammatory molecules and innate immune responsiveness by DCs following
TLR activation.
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Introduction
Dendritic cells (DCs) are the primary professional antigen presenting cells of the
immune system. They have the specialized ability to recognize, capture and process
antigen (Ag) in both peripheral blood and tissues (Figdor et al., 2004). Like other
immune cells, DCs are capable of recognizing microbial components using patternassociated molecular patterns (PAMPs) that are common constituents of bacteria and
viruses. Many PAMPS bind to specific pattern-recognition receptors on DCs, including
Toll-like receptors (TLRs) resulting in immune activation. TLR stimulation leads to upregulation of inflammatory mediators such as the pro-inflammatory cytokines TNF-α and
IL-6. Subsequently, DCs mature and migrate to secondary lymphoid organs, where they
interact with naïve T cells and induce antigen-specific immune responses (Geijtenbeek et
al., 2004). This process of DC maturation includes the sequential loss of
endocytotic/phagocytic receptors, upregulation of costimulatory molecules such as CD40
and CD86, and changes in morphology (Banchereau et al., 2000a).
Toll-like receptors are a major family of cell-bound pattern-recognition receptors that
sense infection via recognition of PAMPs and signal DCs for activation. For example,
TLR3 recognizes viral double-stranded RNA and induces innate immunity, TLR4 is the
primary LPS receptor and TLR9 is the receptor for bacterial DNA (Tsujimoto et al.,
2006). Natural and synthetic ligands such as poly(I:C), LPS and CpG have been used
extensively to model microbial activation of TLR3, TLR4 and TLR9, respectively.
Binding of ligands to these TLRs induces nuclear factor kappa B (NFκB) activation and
subsequent upregulation of numerous immune and inflammatory genes (Banchereau et
al., 2000a; Hoshino et al., 2002). Studies suggest modulation of these immune and
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inflammatory mediators can regulate the generation, development and progression of
several inflammatory diseases including rheumatoid arthritis and atherosclerosis (Sharma
and Li, 2006a; Wang et al., 2006a). Because DCs are key regulators of inflammation and
immunity, one viable approach for the treatment of inflammatory and autoimmune
diseases may be found via the intentional modulation of DC fate and function (Figdor et
al., 2004; Pulendran et al., 1997).
In the last decade there has been a dramatic increase in the use of dietary supplements
including herbal products. Information about the safety and efficacy of most natural
products is vastly inadequate. This insufficiency stems from an unregulated industry,
which is in stark contrast to the tightly regulated pharmaceutical industry. Under the
Dietary Supplement Health and Education Act of 1994, supplements in the U.S. are not
subjected to the same safety requirements that apply to prescription and over-the-counter
medications (Berman and Straus, 2004b; Science, 2004). This means that unlike
conventional drugs, manufacturers of natural products are not required to conduct
rigorous tests to demonstrate safety, efficacy or mechanisms of action (Goldma, 2001;
Science, 2004). Recently, a survey by the U.S. National Academy of Sciences showed
that a majority of consumers believe that herbs are just as safe, effective and costefficient as non-herbal medicines (Klepser and Klepser, 1999). In light of these beliefs
and the increased usage of herbals, rigorous investigation is needed to demonstrate safety,
mechanisms of action and efficacy of these products (Berman and Straus, 2004a).
Ginseng is a widely consumed medicinal herb, both in the United States and
worldwide (Barnes et al., 2004). Over thirteen different species of ginseng have been
identified. Within the Panax genus, extracts of Panax notoginseng typically contain
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higher ginsenoside concentrations than formulations of the more widely used Panax
ginseng (Harkey et al., 2001a). Ginsenoside compounds are saponins which are unique to
the Panax species and are purported to possess the primary pharmacological activity of
ginseng (Harkey et al., 2001a). These compounds are also used as markers for quality
control and standardization of Panax species. Over twenty different saponins have been
identified in notoginseng including ginsenosides, notoginsenosides and gypenoside
(Dong et al., 2003b). Of these, the ginsenosides Rg1, Rb1, Rd1 and notoginsenoside R1
are considered the major bioactive components (Dong et al., 2003b).
To date, several studies exist describing the immunomodulatory effects of ginseng
and ginsenosides; however, specific mechanisms of action of these phytochemicals
remain to be defined. Some of the reported immunologic effects of ginseng and its
constituents include the anti-allergic and anti-inflammatory activities of ginsenoside Rh1
(Park et al., 2004), a reduction in TNF-α levels by ginsenoside Rb1 (Smolinski and
Pestka, 2003b), an increase in both humoral and cell-mediated immune responses by
ginsenoside Rg1 (Kwan, 1995b), and a decrease in phospholipase 2 activity and
neutrophil numbers by whole P. notoginseng extract (Li and Chu, 1999). Additionally,
metabolites of ginseng have been shown to promote human dendritic cell maturation and
Th1 polarization in vitro (Fogel-Petrovic et al., 2004).
Previously, we have demonstrated that P. notoginseng has immunomodulatory
effects on murine macrophages in vitro (Rhule et al., 2006b). In the present study we
hypothesized that notoginseng will reduce the production of inflammatory mediators in
TLR ligand-stimulated murine dendritic cells. To test our hypothesis, DC2.4 cells were
stimulated with LPS, CpG or poly(I:C) and treated with notoginseng. The production of
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pro-inflammatory cytokines as well as the expression of accessory molecules important
in DC activation and function were assessed following notoginseng treatment.
Concentration- and time-dependent studies were carried out using LPS as the prototypical
inflammatory stimulus. Finally, the effects of the purified ginsenosides Rb1 and Rg1 on
LPS-induced TNF-α and IL-6 production were compared to our whole notoginseng
extract. Our results demonstrate for the first time the immunomodulatory effects of
notoginseng and purified ginsenosides on murine DCs in response to several TLR
ligands. These results demonstrate that notoginseng selectively attenuates the production
of pro-inflammatory mediators by DC2.4 cells following stimulation in vitro.
Materials and Methods
Chemicals
NotoG™ extracts from the plant, Panax notoginseng (Burk) F. H. Chen ex C.Y. Wu
& K.M. Feng were generously provided by Technical Sourcing International, Inc. (TSI,
Missoula, MT). Notoginseng was extracted from the root of the plant using ethanol and
contained high levels of the ginsenosides Rb1 and Rg1 (35% and 34% of the whole
extract, respectively) as determined by HPLC analysis (unpublished data). Notoginseng
extracts did not contain detectable levels of Escherichia coli or Salmonella enterica
(unpublished data).

Certification of analyses was approved by Xia Ronglong (QA

manager, TSI). The extract was dissolved in complete media (see below) or culturegrade DMSO (Sigma-Aldrich, St. Louis, MO) and sterile-filtered through a 0.22 µM
Millipore membrane. The purified ginsenosides Rb1 (CAS number: 41753-43-9) and Rg1
(CAS number: 22427-39-0) were purchased from Indofine Chemical Company, Inc.
(Hillsborough, NJ). Lipopolysaccharide (LPS) from Escherichia coli (055:B5) was
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obtained from Sigma-Aldrich, and CpG oligonucleotide and poly (I:C) were purchased
from InvivoGen (San Diego, CA).
Cell Culture
DC2.4 cells, a murine dendritic cell line (Zhenhai et al., 1997), were kindly provided
by Dr. Kenneth Rock (University of Massachusetts Medical Center, Worcester, MA).
Cells were grown in complete media comprised of DMEM (GibcoBRL, Grand Island,
N.Y), supplemented with 10% FBS (Hyclone, Logan, UT), 10 mM HEPES, 2 mM Lglutamine and 50 µg/ml gentamicin (GibcoBRL, Grand Island, N.Y). DC2.4 cells were
maintained at 37˚C in a humidified incubator with 5% CO2. Cells were maintained via
weekly passage and utilized for experimentation at 60-80% confluency.

Cell Activation and Treatment
DC2.4 cells (1 X 106) were cultured in 1 ml complete media for 24 hrs in 6-well
plates. Cells were then stimulated with 1 µg/ml LPS, 0.5 µM CpG or 12.5 µg/ml
poly(I:C) and treated with varying concentrations of notoginseng or purified ginsenosides
for an additional 24 hours. In some experiments, DC2.4 cells were pre-treated with
notoginseng for 24 hrs before LPS stimulation. Supernatants were collected after 24
hours and frozen at -20 0C for subsequent evaluation of cytokines. Additionally, cells
were harvested for flow cytometric evaluation of costimulatory molecules.

Cytokine Assays
Levels of IL-6 and TNF-α in supernatants from cultured cells were analyzed by
enzyme-linked immunosorbent assay

(ELISA). Samples were evaluated per the
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manufacturer’s recommendations using mouse cytokine-specific BD OptEIA ELISA kits
(BD PharMingen, San Diego, CA).

Flow cytometry
The expression of costimulatory molecules on DC2.4 cells was determined by flow
cytometric analysis as previously described (Shepherd et al., 2001). Briefly, DC2.4 cells
were harvested and washed with PAB (1% bovine serum albumin and 0.1% sodium azide
in PBS). Non-specific staining of cells was blocked with 30 µg per sample of purified rat
and/or hamster IgG (Jackson ImmunoResearch, West Grove, PA). Fluorochromeconjugated antibodies to mouse CD86 and CD40, and their corresponding isotype
controls were purchased from BDPharmingen. One hundred thousand events per sample
were collected from viable cells (as determined by light scatter profiles and PI staining)
using a BD FACSAria flow cytometer, analyzed by FACSDiva (version 4.0) software
(BD Biosciences, San Jose, CA) and histograms generated using FCS Express (version 3)
software (De Novo Software, Thornhill, Ontario).

NFκB Assay
DC2.4 cells (1 X 106 cells per well) were stimulated with 1 µg/ml LPS and treated
with 50 µg/ml notoginseng for 0, 30 and 90 minutes in 6-well plates. At each time point,
cells were harvested and nuclear protein extracts prepared using the Active Motif nuclear
lysis kit (Active Motif, Carlsbad, CA). Protein content of nuclear extracts was measured
using a BCA protein assay kit (Pierce, Rockford, IL). NFκB p65 binding activity was
determined using the Active Motif TransAM NFκB p65 kit according to the
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manufacturer’s directions. Briefly, 2.5 µg of nuclear protein was incubated for 1 hour in a
96-well plate coated with the NFκB consensus oligonucleotide sequence (5’GGGACTTTCC-3’). NFκB p65 specific binding was quantified by absorbance (450nm)
using a VersaMax spectrophotometer (Molecular Devices, Sunnyvale, CA).

Statistics
All statistical analyses were performed using GraphPad Prism 4.0a for the Macintosh
(GraphPad Software, San Diego, CA). Differences between two means were analyzed by
Student’s t-test. Data sets with multiple comparisons were evaluated by one-way analysis
of variance (ANOVA) with Dunnett's post test. Values of p < 0.05 were determined to be
significant.

Results
Notoginseng inhibits LPS-induced TNF-α and IL-6 production by DC2.4 cells
In this study, the immunomodulatory effects of notoginseng were characterized using
DC2.4 cells, a murine dendritic cell line. DC2.4 cells were stimulated with 1 µg/ml LPS
and concomitantly treated with 0, 5, 25 or 50 µg/ml notoginseng. In unstimulated DC2.4
cells, notoginseng did not evoke either TNF-α or IL-6 release above basal levels even at
the highest concentration used (Fig. 3-1A and 3-1B, respectively). The addition of LPS
resulted in a 2-fold and 23-fold increase in the production of TNF-α and IL-6,
respectively. Notoginseng significantly inhibited the production of both TNF-α and IL-6
in a concentration-dependent manner. At the highest concentration of notoginseng tested
(50 µg/ml), LPS-induced TNF-α production was reduced approximately 2-fold. In
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addition, nearly a 3-fold reduction in IL-6 production was observed at the 50 µg/ml
concentration. Importantly, the reduction in LPS-induced cytokine production was not
due to cytotoxicity, as viability of cells was similar to controls at all concentrations of
notoginseng examined as assessed by trypan blue exclusion (data not shown).
The effects of notoginseng on TNF-α production are time-dependent
Notoginseng was evaluated for its potential to suppress TNF-α production by DC2.4
at varying time points relative to LPS stimulation. DC2.4 cells were either pretreated with
50 µg/ml of notoginseng for 24 hours prior to LPS addition (-24 hr timepoint), treated
with notoginseng and LPS simultaneously (0 hr), or treated with notoginseng 8 hours
after LPS addition (+8 hrs). All samples were collected 24 hours after LPS exposure. As
expected, concomitant treatment of DC2.4 cell with LPS and notoginseng significantly
suppressed the production of TNF-α after 24 hours of culture by more than 50 percent
(Fig. 3-2). Pretreatment of DC2.4 cells with notoginseng for 24 hours resulted in a 20%
decrease in TNF-α levels. In a separate experiment, removal of notoginseng from the
medium after 24 hours of pre-treatment, but prior to LPS stimulation, also resulted in
suppression of TNF-α following additional 24 hr incubation with LPS (data not shown).
In contrast, addition of notoginseng 8 hours after LPS stimulation did not significantly
inhibit TNF-α secretion, although a trend towards decreased levels was observed (Fig. 32).
Notoginseng modulates the production of TNF-α and IL-6 by DCs stimulated with
additional TLR ligands
Dendritic cells can be activated to secrete pro-inflammatory cytokines by numerous
pathogens expressing different TLR ligands. In this regard, the responsiveness of DCs to
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Figure 3-1.
A.

B.

Figure 3-1. Notoginseng suppresses LPS-induced TNF-α and IL-6 production by
DC2.4 cells. DCs were treated with 0, 5, 25 or 50 µg/ml of notoginseng and/or LPS
(1µg/ml). Supernatants were collected after 24 hours and assayed for TNF-α (A) and IL6 (B) production as described in the Materials and Methods. Data represents mean ±
SEM of three samples. Hash (#) indicates significant differences between LPS-stimulated
and unstimulated cells; asterisk (*) indicates significant differences between the LPSstimulated control- and notoginseng-treated samples (p<0.05). Data are representative of
three independent experiments.
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Figure 3-2.

Figure 3-2. Variable notoginseng treatment affects LPS-induced production of TNFα by DC2.4 cells. Cells were treated with 50 µg/ml notoginseng (NG) at three different
time-points: –24, 0 and 8 hours, relative to LPS stimulation. Supernatants were collected
24 hours after LPS addition and TNF-α levels measured by ELISA. Data represents mean
± SEM of three samples. Hash (#) indicates significant differences between LPSstimulated and unstimulated cells; asterisk (*) indicates significant differences between
LPS-stimulated controls and LPS-stimulated, notoginseng-treated samples (p<0.05). Data
are representative of three separate experiments.
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varied TLR ligands following exposure to notoginseng was examined. DC2.4 cells were
stimulated with 1 µg/ml LPS, 0.5 µM CpG or 12.5 µg/ml poly(I:C) and concomitantly
treated with 50 µg/ml notoginseng. The addition of LPS, CpG and poly(I:C) significantly
increased the production of TNF-α by DC2.4 cells (Fig. 3-3A) (Sparwasser et al., 1998;
Tsujimoto et al., 2006). Notoginseng inhibited the production of TNF-α by 46%, 36%
and 50% for LPS, CpG and poly(I:C), respectively (Fig. 3-3A). There was a significant
increase in the production of IL-6 in LPS and CpG stimulated samples while, barely
detectable levels of IL-6 were present with poly(I:C) stimulation (Fig 3-3B). Notoginseng
reduced the levels of IL-6 in the LPS- and CpG- stimulated samples (Fig 3-3B). In
contrast, notoginseng did not inhibit the limited production of IL-6 by the poly(I:C)stimulated DC2.4 cells (Fig 3-3B). As previously observed, the reduction in TLR-induced
cytokine production was not due to cytotoxicity, as viability of notoginseng-treated cells
was similar to controls as determined by trypan blue exclusion (data not shown).

Expression of TLR-induced costimulatory molecules by DCs is selectively affected by
notoginseng
Because of the observed immunomodulatory effects of notoginseng on TLR-induced
cytokine production, the potential for notoginseng to modulate costimulatory molecule
expression on activated DCs was examined by flow cytometry. DC2.4 cells were treated
concomitantly with each of the 3 TLR ligands and 50 µg/ml of notoginseng.

The

fluorescence intensity of two critical costimulatory molecules, CD40 and CD86, was
assessed. Stimulation of DC2.4 cells with LPS, CpG and poly (I:C) significantly
increased the expression of CD40 (Table 3-1 and Fig. 3-4) (Sparwasser et al., 1998) .
CD86 expression was significantly increased following LPS and poly(I:C) stimulation,
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Figure 3-3.

A.

B.

Figure 3-3. Notoginseng selectively reduces TLR ligand-induced production of TNFα and IL-6 by DC2.4 cells. DCs were unstimulated or stimulated with LPS, CpG or
poly(I:C) and concurrently treated with 50 µg/ml notoginseng (NG) for 24 hours.
Supernatants were collected and assayed for TNF-α and IL-6 production by ELISA. Data
represents mean ± SEM of three samples. Hash (#) indicates significant differences
between stimulated and unstimulated cells; asterisk (*) indicates significant differences
between the TLR ligand-stimulated control- and notoginseng-treated samples (p<0.05).
Data are representative of three independent experiments.
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Table 3-1 Notoginseng selectively alters TLR-induced costimulatory molecule
expression on DC2.4 cells.

Unstimulated
LPS
LPS + Notoginseng
CpG
CpG + Notoginseng
Poly(I:C)
Poly(I:C) + Notoginseng

CD40a
192 ± 2
1484 ± 61#
932 ± 35#*
611 ± 34#
512 ± 13#*
1627 ± 83#
1098 ± 40#*

CD86
1224 ± 28
1630 ± 52#
1295 ± 115#*
1141 ± 33
1408 ± 28#*
1366 ± 49#
929 ± 2#*

DC2.4 cells were not stimulated or stimulated with LPS (1µg/ml), CpG (0.5µM) or
poly(I:C) (12.5 µg/ml) and concomitantly treated with notoginseng (50 µg/ml) for 24
hours. aMean Channel Fluorescence (MCF) was determined by flow cytometry. Data
shown are representative of three independent experiments. Error bars indicate mean ±
SEM of five samples; #, p<0.05 for the comparison of unstimulated and TLR-activated
cells; *, p<0.05 for the comparison of TLR-stimulated cells treated with notoginseng or
untreated.
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Figure 3-4.
A.
LPS

CpG

poly(I:C)

CD40
B.

CD86

Figure 3-4. Notoginseng inhibits the expression of costimulatory molecules on DC2.4
cells following stimulation with TLR ligands. Cells were unstimulated (dashed line) or
stimulated (black line) with LPS, CpG or poly(I:C) and concomitantly treated with 50
µg/ml notoginseng (gray histogram) for 24 hours. Representative histograms
demonstrating the cell surface expression of CD40 (A) and CD86 (B) on activated DC2.4
cells were determined by FACS analysis. Data are representative of three independent
experiments, each consisting of a minimum of three samples per treatment group.
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but not with CpG stimulation (Fig. 3-4). Treatment of unstimulated DC2.4 cells with
notoginseng did not affect CD40 expression; however, CD86 levels were decreased
following exposure to the herbal extract alone (data not shown). Notoginseng treatment
decreased CD40 expression on DCs stimulated with all examined TLR ligands (Fig. 34). Likewise, CD86 expression was reduced on notoginseng-treated DC2.4 cells that were
stimulated by LPS or poly(I:C). In contrast, there was an increase in CD86 expression in
CpG-stimulated, notoginseng-treated samples.

The effects of purified ginsenosides Rb1 and Rg1 on TNF-α and IL-6 production in LPSstimulated DC2.4 cells
Ginsenosides are believed to be responsible for the biological activity of notoginseng.
The notoginseng extract used in our studies is comprised of several ginsenosides,
primarily Rb1 (35%) and Rg1 (34%). Therefore, the potential inhibitory effects of the
purified ginsenosides Rb1 and Rg1 on LPS-induced TNF-α and IL-6 production were
evaluated in DC2.4 cells. To more closely mimic the approximate concentrations of
ginsenosides present in the whole extract, Rb1 and Rg1 were standardized to
concentrations found in 50 µg/ml of the whole notoginseng extract. Following LPS
activation of DC2.4 cells, Rg1 significantly inhibited both TNF-α and IL-6 production
(Fig. 3-5A and 3-5B). In contrast, Rb1 only inhibited the production of IL-6 and was less
potent when compared to Rg1. Neither ginsenoside reduced the production of either
TNF-α or IL-6 as effectively as the whole notoginseng extract. Interestingly, combination
of the purified Rb1 and Rg1 compounds did not significantly decrease the production of
either cytokine.
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Figure 3-5.
A.

B.

Figure 3-5. The production of TNF-α and IL-6 by DC2.4 cells is selectively
suppressed by the whole notoginseng extract and purified ginsenosides. LPSstimulated cells were treated with 50 µg/ml whole notoginseng extract (NG) or purified
Rb1 and/or Rg1 ginsenosides. Supernatants were collected after 24 hours and assayed for
TNF-α (A) and IL-6 (B) production by ELISA. Data represents mean ± SEM of 3
samples. Statistically significant differences (p<0.05) between treatment groups are
indicated by different letters while groups sharing letters are not significantly different.
Data are representative of two separate experiments.
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Notoginseng does not alter LPS-induced NFκB p65 activity in DC2.4 cells
Translocation of NFκB to the nucleus is important for TLR ligand-induced
inflammatory mediator production by dendritic cells. Given that notoginseng decreased
the activation of DCs in our previous experiments and ginseng extracts have been shown
to modulate NFκB activation in other immune cells, the effects of notoginseng on NFκB
p65 nuclear levels were examined. DC 2.4 cells were either unstimulated (0 min), or
stimulated with LPS for 30 or 90 mins and concurrently treated with 50 µg/ml
notoginseng. Samples were then harvested and the nuclear fraction evaluated for NFκB
p65 binding activity. LPS stimulation of DC2.4 cells resulted in increased NFκB p65
levels at both timepoints (data not shown). However, notoginseng did not significantly
affect NFκB p65 activity in the cultured DCs.

Discussion and conclusion
Dendritic cells play an important role in the innate immune response to microbial
pathogens (Granucci et al., 2005). Several studies have reported the effects of ginseng on
various immune cell types; however, no information exists describing its effects on
murine DCs. Previous studies on the effects of notoginseng on innate immunity have
primarily focused on LPS-activated leukocytes. For this reason, we chose to examine the
potential immunomodulatory effects of notoginseng on murine dendritic cells following
stimulation with several TLR ligands, including LPS. Specifically, the effects of
notoginseng on DC2.4 cells were examined following activation of TLR3, TLR4 and
TLR9 by poly (I:C), LPS and CpG, respectively. The production of two critical
inflammatory cytokines TNF-α and IL-6 were evaluated, as they are produced early
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during DC activation. Moreover, TNF-α is involved in the maturation of DCs. Along
with IL-6, TNF-α can rapidly induce expression of costimulatory molecules such as
CD86 on DCs thereby enhancing their interactions with T cells (Fujii et al., 2004). As
LPS is a prototypical inflammatory stimulus, the effects of notoginseng were initially
characterized following TLR4 activation. Notoginseng decreased the production of TNFα and IL-6 by LPS-activated DC2.4 cells. Furthermore, these effects were demonstrated
to be time-and concentration-dependent. Both pretreatment and concomitant notoginseng
treatment significantly reduced TNF-α production. The effects were evident even when
notoginseng was removed from the media prior to LPS stimulation of the dendritic cells
(data not shown). These results suggest that notoginseng may bind to an external receptor
on the DC2.4 cells, may be taken up by the DCs, or potentially both. Additionally, the
actions of notoginseng most likely occur via intracellular changes, and not by binding
LPS and preventing it from activating its receptor, as its presence is not required for the
inhibition of TNF-α. When DCs were exposed to notoginseng 8 hours after LPS
stimulation, no significant inhibitory effects were identified on TNF-α production. These
results suggest that notoginseng may affect early signaling events in DCs following LPSinduced activation.
As previously mentioned, activation of DC can occur by a variety of pathogens
through different TLRs (Napolitani et al., 2005). In these experiments, LPS, CpG and
Poly (I:C) were used to model stimulation of DCs by both bacterial and viral pathogens
(Sioud, 2006). Notoginseng reduced the production of TNF-α by DC2.4 cells in response
to each of the TLR ligands tested while IL-6 production was reduced following LPS and
CpG, but not poly(I:C) stimulation. Because the TLR-induced production of both of these
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pro-inflammatory cytokines was not completely abolished by notoginseng, DC function
may not be significantly diminished. Thus, notoginseng may inhibit the inflammatory
responsiveness of DCs without significantly affecting their ability to initiate adaptive
immunity. If so, this medicinal herb might be expected to benefit individuals infected
with microbial pathogens by limiting the production of inflammatory mediators such as
TNF-α and IL-6 without affecting the generation of pathogen-specific adaptive
immunity.

This possibility is consistent with a previous report demonstrating that

notoginseng-treated mice were less susceptible to the ill effects of experimental sepsis,
effects which the authors attributed to a decreased inflammatory response to infection
(Ahn et al., 2006).
The expression of TLRs can vary within different DC subpopulations (Krug et al.,
2001). Currently, no information exists on the levels of expression for different TLRs in
DC2.4 cells. Further experiments are therefore needed to characterize the level of
expression of TLR3, TLR4 and TLR9 in DC2.4 cells to permit better understanding of
how notoginseng may affect their expression and function. Also, it is becoming widely
accepted that pathogens will trigger multiple TLRs during the course of infection. Thus,
additional experiments designed to evaluate the effects of notoginseng on DCs stimulated
with multiple TLR ligands would be expected to greatly enhance our understanding of
the innate immune responsiveness of DCs.
Interactions between accessory/costimulatory molecules on DCs and their ligands
expressed on T cells are critical for the full activation of T cells (Banchereau et al.,
2000a). Ligation of CD40 on DCs acts as a maturation signal, enhancing antigen
presentation and the expression of other co-stimulatory molecules; while CD86 is
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believed to be the most critical molecule for the amplification of T cell responses
(Banchereau et al., 2000a; Fujii et al., 2004). Previous studies from our laboratory
demonstrated that notoginseng reduced the LPS-induced expression of both CD40 and
CD86 on RAW 264.7 cells (Rhule et al., 2006b). Similarly, CD86 and CD40 expression
on LPS-activated DC2.4 cells was reduced using similar concentrations of notoginseng.
Both molecules on DCs were also reduced by notoginseng treatment following poly(I:C)
stimulation. In contrast, CD40 but not CD86 expression was reduced on DC 2.4 cells
stimulated with CpG. Current studies in our laboratory are evaluating the functional
significance of the notoginseng-induced changes in costimulatory molecule expression on
DCs.
Ginsenosides are unique to the ginseng species and are believed to be the biologically
active components of notoginseng. Because of the wide variability in the types and
concentrations of ginsenosides present in ginseng extracts, it is crucial to define the
immunomodulatory potential of different ginsenosides. In this study, the ginsenoside
Rg1 inhibited the production of both TNF-α and IL-6, while Rb1 only affected the
production of IL-6. Unexpectedly, when Rg1 was combined with Rb1, the inhibitory
effect of Rg1 was lost. This result could be due to a number of factors including
differential effects of Rb1 and Rg1 on cell membrane permeability, on the activation of
disparate receptors and/or signal transduction pathways, or perhaps via the partial
antagonism of Rg1 by Rb1 (Attele et al., 1999). These possibilities are consistent with a
number of studies reporting that complex ginseng extracts can differentially affect
immune cell function based on their specific ginsenoside profiles (Cho et al., 2002a; Cho
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et al., 2001; Guermonprez et al., 2002; Joo et al., 2005). Future studies will therefore be
required to elucidate the complex nature of ginsenoside interactions in dendritic cells.
The transcription factor NFκB plays an important role in the regulation of multiple
signaling pathways that control the activation of many immune cells (Celec, 2004a; Glass
and Ogawa, 2006a). TLR ligands activate NFκB proteins in DCs and subsequently affect
their fate and function (Wang et al., 2007). Several studies with ginseng suggest that it
may inhibit NFκB activation (Ahn et al., 2006; Chung et al., 1998; Keum et al., 2003b).
In our studies, notoginseng did not affect NFκB p65 activation. Thus, it is likely that this
herbal exerts its anti-inflammatory effects through other pathways such as MAPK and
AP1, or through other NFκB family members such as RelB or cRel. Alternatively,
because DC2.4 cells are an immortalized cell line that are not terminally differentiated,
they may respond differently than primary DCs following exposure to notoginseng. This
observation is consistent with recent studies in our laboratory in which notoginseng
reduced NFκB p65 nuclear levels and activity in LPS-stimulated bone marrow-derived
dendritic cells (manuscript in preparation).
In summary, this study demonstrates that notoginseng inhibits the production of
TNF-α and selectively decreases IL-6 production by DCs following TLR activation.
Similarly, notoginseng differentially affected the expression of the costimulatory
molecules CD40 and CD86 on DCs following activation by different TLR ligands.
Collectively, our results demonstrate that notoginseng can decrease the inflammatory
responsiveness of DCs to bacterial or viral stimuli. Further studies are needed to examine
directly if the notoginseng-induced decreases in cytokines and accessory molecules by
DCs alters their ability to initiate T cell-dependent adaptive immunity.
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Abstract
Dendritic cells (DCs) play an important role in facilitating the interaction between the
innate and adaptive arms of the immune system. Many strategies have been used to
manipulate DCs for therapeutic purposes. The medicinal herbal Panax notoginseng has
been extensively studied in macrophages and other cell types for its innate immune
effects. However, limited information exists on the effects of notoginseng on dendritic
cells, and their ability to control the adaptive immune response. In this regard, the
immunomodulatory effects of notoginseng were investigated using murine bone marrowderived dendritic cells (BMDCs). BMDCs were stimulated with 1 µg/ml of LPS and
either pre-treated or concurrently treated with 0-200 µg/ml notoginseng. LPS-induced
production of the pro-inflammatory cytokines TNF-α, IL-1β, IL-6 and IL-12 was
decreased by notoginseng. The cell surface expression of CD40 was reduced in cultures
concurrently stimulated with LPS and treated with notoginseng, while CD86 and MHC II
levels were decreased only following pre-treatment of BMDCs with notoginseng prior to
LPS stimulation. Phagocytosis of FITC-ovalbumin was also reduced in notoginsengtreated BMDCs. Functionally, T cell proliferation in response to notoginseng-treated,
antigen (Ag)-loaded BMDCs was not significantly altered in vitro or in vivo.
Mechanistically, notoginseng decreased BMDC activation independent of glucocorticoid
receptor GCR activation; however, reduced nuclear levels of NFκB p65 were observed in
notoginseng-treated BMDCs when compared to controls. Collectively, notoginseng
reduced the production of inflammatory mediators by BMDCs without altering their
ability to interact with CD4+ T cell in an antigen-specific manner. Therefore, our studies
demonstrate that notoginseng alters the innate but not adaptive functions of DCs.
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Introduction
The induction of T cell-mediated immunity depends on the successful interaction of Agbearing antigen presenting cells (APCs) with Ag-specific T cells (Di Nicola and Lemoli,
2000). DCs are recognized as the primary APCs of the immune system. These cells also
provide an integral link between innate and adaptive immunity (Granucci et al., 2003).
They are important in the mediation of inflammation and have been implicated in
numerous inflammatory diseases (Kuipers and Lambrecht, 2004; Sharma and Li, 2006b;
Thomas et al., 1999). Activated DCs produce various cytokines such as TNF-α, IL-1β,
IL-6 and IL-12, which affect both microbial pathogens and leukocytes. These cytokines
are also influential in the generation of several inflammatory conditions including
atherosclerosis and rheumatoid arthritis (Andreakos et al., 2004a; Munz et al., 2005).
Additional responses of DCs following activation include upregulation of adhesion and
costimulatory molecules such as CD40 and CD86, and also major histocompatibilty
complexes (MHC class I and II) on their cell surface (McLellan et al., 2000). These
molecules are essential for productive Ag-specific interactions to occur between DCs and
T cells (Fujji et al., 2004).
Many DC responses are regulated at the transcriptional level and, in particular, by the
transcription factor, nuclear factor kappa B (NFκB) (West et al., 2004). When activated
by classic inflammatory stimuli such as TNF-α and LPS, NFκB is released from the
inhibitory protein IκB and translocates from the cytoplasm to the nucleus where it binds
and induces transcription of specific target genes. This results in the upregulation of
numerous immune and inflammatory genes. Pro-inflammatory mediator induction by
NFκB activation can be affected by the glucocorticoid receptor (GCR) (Glass and
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Ogawa, 2006b). Signaling through the GCR results in potent inhibition of the
inflammatory response as well as attenuated DC function (Glass and Ogawa, 2006b;
Valledor and Ricote, 2004).
Several natural and synthetic chemicals are capable of modulating the immune system
(Patwardhan and Gautam, 2005). Currently, most compounds used to combat
immunologic diseases are synthetic and biosynthetic pharmaceutical products. However,
the use of herbal products is increasing, with consumer sales reaching previously unseen
numbers (Paterson and Anderson, 2005). In spite of this increased usage, the effects of
many of these herbals on the immune system have not been well characterized. As many
of these herbals have the potential to modulate the immune system, it is important to
understand their mechanisms of action and potential immunotoxic effects.
Ginseng has been used as a medicinal for over 2000 years in Asian countries and is
now becoming increasingly popular in Western countries such as the United States (Sato
and

Miyata,

2000).

Numerous studies have shown

that

ginseng possesses

immunomodulatory properties (Hofseth and Wargovich, 2007; Jie et al., 1984; Liou et
al., 2005). These biological effects are most likely mediated by ginsenosides, the
purported therapeutic phytochemicals in ginseng (Dong et al., 2003a). There are thirteen
known species of ginseng with the Panax ginseng, Panax quinquefolium and Panax
notoginseng being the three most popular medicinal species. Of these three, Panax
notoginseng possesses the highest concentration of ginsenosides (Harkey et al., 2001b).
Several studies exist describing the effects of Panax notoginseng and ginseng derivatives
on various immune cell types. These studies primarily involve the anti-inflammatory
effects of notoginseng, specifically its reduction of cytokine production and inflammatory
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enzymes such as iNOS and COX-2 (Park et al., 2005). Currently, no information exists
regarding the effects of notoginseng on the innate function of murine DCs or their
capacity to interact with T cells in an Ag-specific manner.
To address this deficiency, we have examined the immunomodulatory effects of
Panax notoginseng in murine bone marrow-derived dendritic cells (BMDCs). BMDCs
were stimulated with LPS and concurrently treated with notoginseng. Production of the
pro-inflammatory cytokines TNF-α, IL-1β, IL-6 and IL-12 and expression of the cell
surface molecules CD40, CD86 and MHCII were analyzed following notoginseng
exposure. The effects of notoginseng on antigen uptake and Ag-specific activation of T
cells were also evaluated. Studies have suggested that alteration of NFκB activation in
ginseng-treated macrophages may be responsible for decreased production of
inflammatory mediators (Oh et al., 2004a; Park et al., 2005). Therefore, the effects of
notoginseng on NFκB activation were investigated in BMDCs. Additionally, the GCR
blocker RU486 (mifepristone) was utilized to determine whether notoginseng’s activity
occurred through GCR-mediated mechanisms. Our results demonstrate that notoginseng
inhibits the innate immune responsiveness of DCs without altering their antigen-specific
adaptive immune function.

Materials and methods
Mice
C57BL/6 mice aged 6-12 weeks old were bred and maintained in the animal research
facilities at the University of Montana. Mice were housed under specific pathogen-free
conditions and maintained on 12-hour dark/light cycles. Standard laboratory food and
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water were provided ad libitum. All protocols for the use of animals were approved by
the University of Montana Institutional Animal Care and Use Committee.

BMDCs
Bone marrow cells (BMCs) were collected from the femur and tibia of C57BL/6 mice for
in vitro use, by flushing out the bone marrow with cRPMI using a 30-gauge needle.
BMCs were then layered on a density gradient using lympholyte reagent (Cedarlane
laboratories limited, Ontario, Canada) and centrifuged at 800 X g for 20 minutes. The
lymphocyte layer was collected and washed with cRPMI. To generate myeloid-derived
BMDCs, BMCs were grown in cRPMI with 30 ng/ml granulocyte-macrophage colony
stimulating factor (GM-CSF) (Leinco, St Louis, Missouri) at 1X10 6 cells per ml in T75
flasks. Media and growth factor were removed and replenished on days 3 and 5. Cells
were harvested after 7 days and DCs purified using (90% CD11c+) CD11c-APC
antibodies and anti-APC Miltenyi magnetic beads (Miltenyi Biotec, Auburn, CA)
according to the manufacturer’s instructions.
Chemicals
Noto-GTM extracts from the plant Panax notoginseng (Burk.) F.H. Chen ex C.Y. Wu &
K.M. Feng were kindly supplied by Technical Sourcing International, Inc. (TSI,
Missoula, MT). Notoginseng was extracted from the root of the plant using ethanol and
standardized to contain Rb1 and Rg1 ginsenosides at 35 and 34% of the whole extract,
respectively. Quantification of Rb1 and Rg1 in the notoginseng extract was determined
by high-performance liquid chromatography analysis by TSI. Certification of analyses
was approved by Xia Ronglong (QA manager, TSI). Escherichia coli (E. coli) and
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Salmonella enterica were undetectable in the notoginseng preparation (unpublished data).
The extract was dissolved in complete media (see below) and subsequently sterile-filtered
through a 0.22 µM Millipore membrane. Lipopolysaccharide (LPS) from E. coli
(055:B5); whole ovalbumin, RU486 and dexamethasone (DEX) were obtained from
Sigma-Aldrich. Custom synthesized OVA323-339 peptide was purchased from Mimotopes,
San Diego, CA.

Cell Activation and Treatment
BMDCs (1 X 106 cells per well) were stimulated with 1 µg/ml LPS and treated with 0,
100, 150 or 200 µg/ml notoginseng for 24 hrs at 37 0C and 5% CO2 in 6-well plates.
After 24 hrs, cells were harvested for RT-PCR and FACS analyses and supernatants were
collected for evaluation by ELISA. BMDC treatment with the GCR antagonist, RU486,
and the GCR agonist, DEX, as described in previously published conditions (Pan et al.,
2001). Briefly, RU486 (1 µM) was added to BMDCs 15 minutes prior to notoginseng or
DEX (100 nM) treatment and stimulation with LPS. DMSO (less than 0.1%) was added
to unstimulated and LPS-stimulated samples to serve as controls in these experiments, as
DEX and RU486 were dissolved in DMSO. For BMDC antigen processing and
presentation experiments, notoginseng was removed from the media after 24 hrs and
replaced with fresh media. Cells were then pulsed with 100 µg/ml whole OVA or 50
µg/ml OVA323-339 peptide for 24 hrs. BMDCs were subsequently harvested, counted and
prepared for assay. The viability of BMDCs used in all experiments was greater than
90% as determined by Trypan blue exclusion.
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Cytokine Assays
Levels of TNF-α, IL-1β, IL-2, IL-6 and IL-12 in the supernatants were measured by
enzyme-linked immunosorbent assay (ELISA). Samples were analyzed per the
manufacturer’s instructions using mouse cytokine-specific BD OptEIA ELISA kits (BD
PharMingen, San Diego, CA).

Flow Cytometry
Detection of accessory molecule expression on BMDCs by fluorescent activated cell
sorting (FACS) analysis was performed as previously described (Shepherd et al., 2001).
Briefly, BMDCs were harvested and washed with PAB (1% bovine serum albumin and
0.1% sodium azide in PBS). Cells were blocked with 30 µg of purified rat and/or hamster
IgG (Jackson ImmunoResearch, West Grove, PA) for 10 minutes to eliminate nonspecific staining. Optimal concentrations of flurochrome-conjugated monoclonal
antibodies were used to stain cells for an additional 10 minutes. The antibodies used in
these experiments were CD86-APC, CD40-PE, MHCII-PE, CD4-PE, CD11c-APC,
CD44-PB, CD62L-PE and their corresponding isotype controls (BDPharmingen, San
Diego, CA). One to five hundred thousand viable cells per treatment (as determined by
light scatter profiles and propidium iodide staining) were analyzed using a BD FACSAria
flow cytometer and FACSDiva software (BD Biosciences, San Jose, CA).

NFκB Activity Assay
BMDCs (1 X 106 cells per well) were stimulated with 1 µg/ml LPS and treated with 150
µg/ml notoginseng for 0, 1 or 2 hrs at 37 0C and 5% CO2 in 6-well plates. At each time-
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point, cells were harvested, lysed and proteins extracted using the ActiveMotif nuclear
lysis kit (Active Motif, Carlsbad, CA). The protein content of the nuclear extract was
measured using a BCA protein assay kit (Pierce, Rockford, IL). Nuclear protein (2.5
µg/ml per well) was then added to the Active Motif TransAM NFκB p65 kit (Active
Motif, Carlsbad, CA) and assayed according to the manufacturer’s specifications. Briefly,
2.5 µg of nuclear protein was incubated in a 96-well plate containing the NFκB
consensus site (5’-GGGACTTTCC-3’) for 1 hour. This was followed by a 1-hour
incubation with a primary antibody that recognizes NFκB p65 bound to target DNA. The
peroxidase-conjugated secondary antibody was added for an hour, after which samples
were developed and analyzed by spectrophotometery.

Immunoblotting
In some experiments, nuclear extracts from the treated BMDCs were also assayed for
NFκB p65 protein by Western blotting. For these assays, 10 µg of protein was loaded
onto a SDS-PAGE gel and blotted onto 0.2 µm polyvinylidene difluoride transfer
membrane (Biorad, Hercules, CA). Membranes were blocked using 10% nonfat dried
milk in PBS with 0.05% Tween (PBST), then incubated overnight at 40C with either
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) to NFκB p65 antibody (1:500) or
β-actin (1:4000). The membrane was washed and incubated with either peroxidaseconjugated anti-rabbit IgG (Jackson Immunoresearch, 1:1000) or anti-mouse IgG
(Southern Biotechnologies). Membranes were exposed for 1-5 mins and processed using
Fuji film imaging software.
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In vitro Antigen Presentation Assay
BMDCs were untreated or pretreated with notoginseng for 24 hours, washed to remove
notoginseng, then loaded with Ag (whole ovalbumin at 100 µg/ml or ova peptide at 50
µg/ml) overnight. T cells were isolated from the spleens of OT-II T cell receptor
transgenic mice and purified using CD4-PE antibodies (BD Pharmingen, San Diego, CA)
and anti-PE beads (Miltenyi Biotec, San Diego, CA). T cells (2 X 105) were co-cultured
with BMDCs (2 X 105) cells in 96 well plates. After 72 hours, cells were pulsed with
1µCi [3H] thymidine (Amersham, Piscataway, NJ) for 24 hours. Cells were harvested and
[3H] thymidine incorporation measured via liquid scintillation.

Adoptive Transfer of Ag-loaded donor DCs and Ag-specific T cells
The protocol for adoptive transfer was modified from a previously described method
(Shepherd et al., 2000). Briefly, BMDCs were exposed to 100 µg/ml of notoginseng for
24 hours. Cells were treated with 50 µg/ml of OVA peptide for an additional 24 hours.
Splenic OTII CD4+ T cells were harvested from OT II/Thy1.1 mice and enriched using
Miltenyi magnetic beads. OT II T cells (2 X 106 per mouse) were resuspended in HBSS
and injected iv into age- and sex-matched, CD45.1 congenic host mice on day -1 relative
to immunization. Host-mice were immunized on day 0 with ova peptide-loaded BMDCs
(1 X 106) via rear footpad injection. On day 4 post-immunization, popliteal lymph node
cells were harvested from the host mice and analyzed by flow cytometry. Brachial lymph
node cells were also harvested and evaluated as unactivated controls. Subsequent analysis
of the Ag-loaded BMDCs and Ag-specific T cells was based on the phenotypic
expression of CD45.2+/CD11c+ donor dendritic cells and CD4+/Thy1.1+ OT II T cells,
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respectively. Cells from the host were excluded based on their expression of CD45.1 and
Thy 1.2 cell surface proteins.

Statistics
All statistical analyses were performed using GraphPad Prism 4.0a for the Macintosh
(GraphPad Software, San Diego, CA). Data represents the mean ± SEM of 3 samples for
3 independent experiments unless otherwise stated. Differences between treatment groups
were analyzed by Student’s t-test. Data sets with multiple comparisons were evaluated by
one-way analysis of variance (ANOVA) with Dunnett's test. Values of p < 0.05 were
determined to be significant.

Results
Notoginseng suppresses the LPS-induced production of pro-inflammatory cytokines by
BMDCs
Cytokines are important mediators in the orchestration of an immune response. To
investigate the effects of notoginseng on the production of cytokines by dendritic cells,
BMDC were stimulated with 1 µg/ml LPS and concurrently treated with notoginseng. As
shown in Fig. 4-1, activation of BMDCs with LPS resulted in significant increases in the
production of TNF-α, IL-1β, IL-6 and IL-12, when compared to unstimulated controls.
At the highest concentration of notoginseng tested (200 µg/ml), the LPS-induced
production of IL-1β, IL-6 and IL-12 was decreased by approximately 90%. Notoginseng
also reduced TNF-α production by BMDCs although to a lesser degree than observed for
the other pro-inflammatory cytokines. No cytotoxicity was observed at any of the
concentrations of notoginseng used in our study as assessed by Trypan blue exclusion
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Figure 4-1.
A.

C.

B.

D.

Figure 4-1. Notoginseng modulates LPS-induced cytokine production by BMDC.
Cells were stimulated with LPS (1 µg/ml) and concomitantly treated with 0, 100 or 200
µg/ml of notoginseng. Supernatants were collected after 24 hours and assayed for TNF-α,
IL-1β, IL-6 and IL-12 levels by ELISA. Data represent mean ± SEM of 3 samples. #
Indicates significant differences between stimulated and unstimulated cells (p < 0.05), *
indicates significant differences between the LPS-stimulated, control- and notoginsengtreated samples (p < 0.05). Data are representative of 3 independent experiments.
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(data not shown). Also, notoginseng did not significantly affect cell recoveries of
BMDCs when compared to control treated samples.

BMDC expression of key accessory molecules is affected by notoginseng
To determine the effect of notoginseng on accessory molecule expression on DCs,
BMDCs were stimulated with LPS and concurrently treated with 200 µg/ml of
notoginseng for 24 hours.

Activation markers on BMDCs were analyzed by flow

cytometry. A significant increase in CD40, CD86 and MHC II cell surface expression
was observed following LPS stimulation of BMDCs (Fig. 4-2 and Table 4-1). CD40
expression was reduced by 58% on BMDCs treated concurrently with notoginseng and
LPS while CD86 and MHC II were unaffected by the herbal treatment. In some
experiments, cells were pretreated with notoginseng for 20 hrs prior to LPS stimulation to
determine if notoginseng exposure prior to activation differentially affected cell surface
molecule expression. Pretreatment of BMDCs resulted in an even greater reduction in the
expression of CD40, while also significantly decreasing CD86 and MHCII expression.
Reduced uptake of FITC-conjugated whole ovalbumin by notoginseng-treated BMDCs
To assess whether notoginseng reduced antigen uptake, a primary function of dendritic
cells, BMDCs were incubated with FITC-conjugated whole ovalbumin (FITC-ova).
Fluorescence intensity was used to assess the phagocytosis of FITC-ova by BMDCs via
both flow cytometry and fluorescence microscopy analyses (Fig. 4-3). A decrease in
fluorescence intensity was observed in both the 50 and 100 µg/ml notoginseng-treated
groups when compared to controls as determined by light microscopy (Fig. 4-3A). This
effect was quantitatively confirmed by flow cytometry, as a 3-fold reduction in mean
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Table 4-1. Notoginseng differentially affects the expression of LPS-induced
accessory molecules on BMDCs.
CD40
MCFb
Unstimulated a 683 ± 12

CD86
MCF

Percent MHC II+c

5991 ± 105

17 ± 1.7

LPS

8985 ± 1305#d 11280 ± 488 # 27 ± 0.8 #

LPS + NG

3750 ± 172#*

10210 ± 386 # 24 ± 1.0 #

LPS + NG
PRE-TREAT

2266 ± 105#*

8872± 384#*

a

11 ±0.6#*

BMDC were either unstimulated, stimulated with LPS only, stimulated with LPS and

concomitantly treated with notoginseng (200 µg/ml), or pre-treated with notoginseng for
20 hours prior to LPS stimulation. Cells were harvested 24 hour following stimulation
with LPS.
b
c

Mean Channel Fluorescence (MCF) as determined by flow cytometry
Percentage of BMDCs expressing high levels of MHC II as determined by flow

cytometry.
d

Data shown are representative of three independent experiments. Error bars indicate

mean ± SEM of 3 samples; #, p < 0.05 for the comparison of unstimulated and LPSactivated cells; *, p < 0.05 for the comparison of LPS-stimulated cells to notoginsengtreated, LP-stimulated cells.
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Figure 4-2.

CD40

CD86

MHC II high

LPS + Unstimulated

LPS + NG

LPS + NG Pretreat

Figure 4-2. Effects of notoginseng on LPS-induced expression of accessory
molecules on BMDCs. Cells were treated with notoginseng (200 µg/ml) either
concurrently or 20 hours prior to LPS stimulation. Cells were stimulated with LPS for 24
hours and CD40, CD86 and MHC II expression was assessed by flow cytometry. The
broken lines represent unstained controls; solid lines represent LPS-stimulated samples,
and dotted lines represent LPS-stimulated, notoginseng treated samples. Data are
representative of 2 separate experiments with 3 samples per treatment group.
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Figure 4-3.
Ova

Ova + 50NG

Ova + 100NG

A.

B.
2067 ± 161

872 ± 50

663 ± 53

Figure 4-3. Notoginseng reduces FITC-conjugated ovalbumin uptake by BMDCs.
Cells were incubated with FITC-conjugated whole ovalbumin (FITC-Ova) or FITC-Ova
and notoginseng (NG) 200 µg/ml. BMDCs were harvested and fluorescence intensity was
visualized by fluorescence microscopy (A) and quantified by flow cytometry (B). In Fig.
B, the dotted lines represent non-ova-exposed cells; solid lines represent ova exposed
cells with or without notoginseng treatment. Data represents mean ± SEM of 3 samples. *
indicates significant differences between LPS-stimulated controls and LPS-stimulated,
notoginseng-treated samples (p < 0.05). Data are representative of 2 separate
experiments.
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channel fluorescence intensity was detected between controls and cells concurrently
exposed to 100 µg/ml notoginseng and FITC-ova (Fig. 4-3B).
NFκB activation in BMDCs is decreased by notoginseng treatment
NFκB activation plays an important role in regulating the expression of many
inflammatory molecules. To determine if the effects of notoginseng might be mediated
through decreased NFκB activation, BMDCs were stimulated with LPS or LPS and 200
µg/ml of notoginseng for 0-2 hrs and NFκB p65 activity was assessed (Fig. 4-4). Nuclear
extracts were evaluated to determine whether notoginseng altered NFκB p65-binding
activity to an oligonucleotide containing the NFκB consensus-binding site. A 2.4-fold
increase in NFκB binding activity was detected in the LPS-stimulated samples when
compared to the unstimulated controls (Fig. 4-4A). Notoginseng treatment significantly
decreased NFκB p65 binding activity in LPS-stimulated BMDCs. Reduced levels of
nuclear NFκB p65 protein were also observed in notoginseng-treated BMDCs as
determined by Western blotting (Fig. 4-4B).

Notoginseng does not inhibit BMDC activity via the glucocorticoid receptor
Previous reports have demonstrated binding and activation of the GCR by ginsenosides
(Chung et al., 1998; Kim et al., 1997). Additionally, GCR activation leads to decreased
inflammatory mediator production by DCs, similar to the effects of notoginseng.
Therefore, the role of GCR activation was assessed in notoginseng-treated BMDCs. To
determine whether notoginseng acts through GCR activation, LPS-stimulated BMDCs
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Figure 4-4.
A.

B.

No LPS
0hr

LPS

LPS NG
1 hr

LPS

LPS NG
2 hrs

NFκB
β-actin

Figure 4-4. NFκB activation is reduced by notoginseng treatment. BMDCs were
stimulated with LPS (1 µg/ml) and concomitantly treated with notoginseng (150 µg/ml).
Cells were harvested after 2hrs and nuclear proteins were isolated. NFκB p65 activation
was measured using the TransAM activity ELISA (A), and nuclear protein levels were
determined using by Western blotting (B). # Indicates significant differences between
LPS-stimulated and unstimulated cells (p < 0.05); * indicates significant differences
between LPS-stimulated controls and LPS-stimulated, notoginseng-treated samples (p <
0.05). Data are representative of 3 separate experiments.
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Figure 4-5.

A.

B.

C.

Figure 4-5. The effects of notoginseng on BMDCs are not mediated through the
GCR. BMDCs were stimulated with LPS (1 µg/ml) and concomitantly treated with
notoginseng (200 µg/ml) or dexamethasone. RU486 was added to some samples 15
minutes before addition of LPS, notoginseng or dexamethasone. Samples were harvested
at 24 hours and TNF-α and IL-6 levels were measured by ELISA. CD40 expression was
determined by flow cytometry. Data represents mean ± SEM of 3 samples. # Indicates
significant differences between LPS-stimulated and unstimulated cells (p < 0.05); *
indicates significant differences between LPS-stimulated controls and LPS-stimulated,
notoginseng-treated samples (p < 0.05). Data are representative of 2 separate
experiments.
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were either treated with 200 µg/ml of notoginseng, or 200 µg/ml of notoginseng and
RU486. LPS-stimulated BMDCs were also treated with DEX and RU486 as comparative
control as these compounds have been widely used to investigate whether the effects of a
particular agent occurs via GCR binding (Kim et al., 2001; Pan et al., 2001).

As

expected, DEX significantly reduced BMDC production of TNF-α and IL-6, as well as
their expression of CD40, with effects that were blocked with the co-administration of
RU486 (Fig. 4-5). Notoginseng also significantly reduced TNF-α and IL-6 levels and
CD40 expression. In contrast to DEX, however, RU486 did not reduce the inhibitory
effects of notoginseng, as would be predicted if notoginseng acted through the GCR (Fig
4-5).

The effects of notoginseng treated BMDCs on antigen-specific T cell proliferation in vitro
A primary function of a DC is to uptake antigen and present it to T cells, culminating in
the generation of a successful adaptive immune response. To investigate whether
notoginseng affected Ag processing and presentation by DC, BMDC were treated with
200 µg/ml notoginseng for 24 hours and exposed to Ag in the form of ova peptide (OP)
or whole ovalbumin (WO). Antigen-loaded BMDC were then cultured with ova-specific
OTII T cells and T cell proliferation evaluated via [3H]-thymidine incorporation. A 3-fold
and 9-fold increase in T cell proliferation was observed using OP- and WO- loaded
BMDCs, respectively (Fig. 4-6A). While a trend towards decreased T cell proliferation
was determined for cultures containing Ag-exposed, notoginseng-treated BMDCs, there
were no significant effects when compared to controls. There was also no difference in
IL-2 production between control and notoginseng-treated groups (Fig. 4-6B).
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Figure 4-6.
A.

B.

Figure 4-6. APC function of BMDCs is not affected by notoginseng in vitro. DCs
were treated with notoginseng (200 µg/ml) for 24 hours after which the herbal extract
was removed from the cultures. BMDCs were then stimulated with 100 µg/ml of whole
ovalbumin (WO) or ova peptide (OP) for an additional 24 hours. BMDCs were harvested
and co-cultured with CD4+ T cells from OT II mice. After 3 days, T cell clonal
expansion was measured as described in materials and methods (A) and supernatants
analyzed for IL-2 production by ELISA (B). # Indicates significant differences between
antigen exposed and unstimulated cells; * indicates significant differences between
antigen-loaded controls and antigen loaded, notoginseng-treated samples (p < 0.05). Data
are representative of 2 separate experiments; 3 samples per group.
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Notoginseng does not affect BMDC migration or APC function in vivo
Immature DCs are capable of antigen capture in the periphery and subsequent migration
to draining lymphatic tissue (Banchereau et al., 2000c). In lymph nodes, DCs activate
antigen-specific T cells, thereby initiating T cell mediated immunity. To test the ability of
notoginseng-treated DC to migrate to lymph nodes and interact with antigen specific T
cells in vivo, donor BMDCs were treated with 200 µg/ml of notoginseng for 24 hours,
and susequently loaded with ova peptide. Congenic host mice that had been adoptively
transferred with ova-specific CD4+ T cells were immunized with ova-loaded BMDCs.
Mice were harvested 4 days following BMDC immunization and both the proximal and
distal lymph nodes were removed for evaluation of BMDC-T cell interactions.
Differences in the expression of cell surface molecules on donor and host mice, allowed
for the segregation of donor DC (CD11c+/CD45.2+) and T cells (CD4+/Thy1.1+) from
cells from the host mouse (CD45.1+/Thy 1.2+). Therefore, the effects of notoginseng
treatment on BMDCs fate and function in vivo could be exclusively evaluated. Ag-loaded
BMDCs increased percentages and numbers of OT II T cells in the draining popliteal
lymph nodes of host mice when compared to the distal brachial lymph nodes which
served as unactivated controls (data not shown).

No significant differences were

observed in the percentage or number of CD11c+ donor DCs present in the popliteal
lymph nodes between control DCs and notoginseng-treated DCs (Figs. 4-7A and 4-7B).
Additionally, there were no significant differences in the clonal expansion of
OTII/Thy1.1 T cells in mice receiving control-treated and notoginseng-treated BMDCs
(Fig. 4-7 C/D). Furthermore, no differences were observed in the activation of ovaspecific
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Figure 4-7.
A.

B.

C.

D.

Figure 4-7. Notoginseng does not alter the ability of BMDCs to migrate to lymph
nodes and activate T cells in vivo. CD4+ T cells from OTII/Thy1.1 were adoptively
transferred into congenic CD45.1 host mice, 24 hours before immunization with ovaloaded BMDCs (OP) that were untreated (-) or exposed to notoginseng (NG) (200
µg/ml). On day 4 post-immunization, popliteal lymph node cells were harvested from
host mice and analyzed by flow cytometry. Analysis was based on differences in
phenotypic expression of cell surface molecules between donor DCs (CD45.2/CD11c)
(A/B) and donor T cells (CD4/Thy1.1) (C/D) and cells from the host mice (CD45.1/Thy
1.2). Data are representative of 2 separate experiments, each with 6 animals per treatment
group.
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T cells between controls and notoginseng-treated cells as defined by the expression of the
activation markers, CD62L and CD44, on the OT II/Thy 1.1 T cells (data not shown).

Discussion and conclusion
DCs provide critical functions for the effective defense against pathogens via both
innate and adaptive immune responses. In this study we demonstrated that notoginseng
decreased the level of pro-inflammatory cytokine production and cell surface molecule
expression by dendritic cells without altering their T cell stimulatory capabilities.
Cytokines are soluble mediators that are involved in many biological processes in
particular inflammation. TNF-α is a preformed cytokine and is released immediately
after activation of phagocytes (Abass et al., 1994). In many inflammatory disease
processes such as arthritis, TNF-α is described as being the apex of the pro-inflammatory
cascade (Andreakos et al., 2004a). Inhibiting TNF-α has been shown to decrease
production of other cytokines including IL-1β, IL-6 and even TNF-α itself (Abass et al.,
1994). Notoginseng reduced the secretion of TNF-α by BMDCs, but displayed an even
greater inhibition of IL-1β, IL-6 and IL-12. IL-10 production was also inhibited by
notoginseng (data not shown). These data are consistent with previous results from our
laboratory demonstrating that notoginseng significantly attenuates the production of
TNF-α and IL-6 by LPS-stimulated murine macrophages (Rhule et al., 2006b). DCs
have increasingly been shown to participate in inflammatory disease processes. As such,
inhibition of pro-inflammatory cytokines suggests a plausible mechanism for the
described anti-inflammatory effects of notoginseng (Jin et al., 2007; Li and Chu, 1999;
Wang et al., 2006b).
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Accessory molecule expression is necessary for full T cell activation by DCs. The
interaction of CD40 on DCs with CD154 (CD40L) on T cells is crucial in sustaining a
productive T cell response (Banchereau et al., 2000b). Additionally, CD40 is involved in
the amplification and regulation of inflammatory responses (van Kooten and Banchereau,
2000). In our experiments, CD40 expression was decreased following notoginseng
treatment of BMDCs, while expression of CD86 and MHC II expression was less
sensitive. These results suggest that notoginseng may inhibit the expression of cell
surface molecules via different mechanisms, but it is particularly effective in decreasing
CD40 expression. One possible explanation for the selective effects of notoginseng on
CD40 is through decreased activation of NFκB, especially the RelB. Interestingly, RelB
knockout mice lack CD40 expression, yet express normal levels of CD86 and MHC II
(Martin et al., 2003; O'Sullivan and Thomas, 2003). It is therefore plausible that
notoginseng alters CD40 expression on DCs via modulation of RelB; however, this
possibility remains to be tested.
Notoginseng significantly reduced BMDC cytokine production and expression of
CD40, effects that can promote T cell tolerance (O'Sullivan and Thomas, 2003). There
was also a decrease in phagocytosis, which is consistent with a report on the effects of
metabolized ginsenosides on human DCs by Takei and colleagues (Takei et al., 2004).
Several reports have described the inhibitory effects of ginseng on NFκB p65 activity
(Ahn et al., 2006; Oh et al., 2004a; Park et al., 2005). As many DC functions are
mediated through NFκB p65 signaling, the effects of notoginseng on this protein were
examined in BMDCs. In our study, notoginseng significantly decreased NFκB p65
nuclear levels and activity in BMDCs. Recent studies suggest that the RelA subunit of
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NFκB is crucial for the expression of inflammatory cytokine genes, but not T cell
stimulatory genes such as CD86 and MHC II (Wang et al., 2007). Alternatively,
notoginseng could be selectively affecting different NFκB components such as RelB, or
other signaling pathways such as MAP kinase and AP-1 as recently demonstrated in
astroglial cells (Jung et al., 2006). Additional experiments focused on defining the effects
of notoginseng on intracellular signaling events are therefore warranted.
Glucocorticoids are hormones that are naturally released during the initiation and
regulation of an immune response. These hormones activate the GCR thereby reducing
the synthesis of inflammatory mediators via repression of gene transcription (Smoak and
Cidlowski, 2004). Previous studies in FTO2B cells, a rat hepatoma-derived cell line,
showed that the ginsenoside Rg1, a component of ginseng, can effectively activate the
glucocorticoid receptor (Chung et al., 1998; Lee et al., 1997). In our study, RU486
completely inhibited the effects of DEX on CD40. However, the effects on TNF-α and
IL-6 were not completely reversed. Blockade of the GCR with the antagonist RU486
failed to reduce the inhibitory effects of notoginseng on BMDCs. These results are
consistent with a previous study showing that ginseng does not mediate its effects via
GCR activation, but reverses the down-regulation of the activated GCR (Ling et al.,
2005). Additionally, as we previously reported that, individual ginsenosides such as Rg1
can differentially affect APCs in the presence of other ginsenosides such as Rb1 (Rhule et
al., 2006b).
Alternatively, notoginseng may indirectly affect GCR activity by binding to locations
other than the active site. If binding of notoginseng did not occur via the active site of the
GCR in BMDCs, then RU486 would not affect its activity in BMDCs. Unexpectedly, the
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combined treatment of LPS-stimulated BMDCs with RU486 and notoginseng resulted in
further decreases in the expression of CD40. While we have not directly studied what
caused this effect, as RU486 can also block glucocortiocoid and progesterone receptorbinding sites, there may be more notoginseng available for activity at other complexes.
This may have led to more unbound notoginseng being available to interact with other
receptors responsible for modulating the immune system, resulting in the more
pronounced decrease of CD40 observed with the addition of both RU486/notoginseng.
DCs are the primary APCs involved in the initiation of T cell activation. Notoginseng
treatment reduced cytokine production, phagocytosis and costimulatory molecule
expression by BMDCs. As alterations of these DC functions can directly affect their
activation of T cells, we examined the effects of notoginseng on APC activity.
Notoginseng treatment did not affect the ability of BMDCs to stimulate antigen specific
T cell proliferation in vitro and in vivo. There were also no effects on activation molecule
expression on T cells interacting with notoginseng-treated BMDCs. Our results are
inconsistent with other studies suggesting that notoginseng and its components possess
adjuvant properties (Qin et al., 2006; Sun et al., 2005; Yang et al., 2007a). This
discrepancy could be due to several factors including the ratios of ginsenosides in our
notoginseng extract being different from those used in other experiments. This
explanation is in line with previous experiments by our laboratory demonstrating that
ginsenoside Rb1 and Rg1 can have different properties in regards to proinflammatory
cytokine inhibition induced by LPS in RAW264.7 and DC2.4 cells (Rhule et al.,
2006b)(submitted article). Additionally, in a study by Cho et al ginsenosides were shown
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to differentially regulate lymphocyte proliferation in vitro (Cho et al., 2002b). This
demonstrates the potential for different ginsenosides to possess varied effects.
DCs in vivo had decreased CD40 expression at the end of the 4 day incubation period
with T cells, while CD86 and MHCII were expressed at similar levels on the untreated
and notoginseng-treated DCs (data not shown). Importantly, the decreased CD40
expression on DCs clearly had no effect on the activation of T cells. This is significant, as
interaction of CD40 on APCs with CD40L on T cells is necessary for full T cell
activation (Fujji et al., 2004). Our experiments therefore raise questions of how much
CD40 expression is necessary to fully activate T cells and whether decreased expression
leads to immunosuppression. There are several studies describing the effects of Ginseng
on T cell proliferation and reduced function/activation of APCs such as macrophages
(Cho et al., 2002b; Martin et al., 2003; Oh et al., 2004a; Rhule et al., 2006a). However,
the effects of notoginseng on the interactions of APCs with antigen-specific T cells have
not been determined. Our experiments provide novel information, demonstrating that
although innate functions of DCs are decreased by notoginseng, adaptive immune
functions are unaffected.
There is continued interest in the effects of natural products due to their therapeutic
potential. Our study demonstrates that notoginseng treatment of BMDC can inhibit
specific mediators of inflammation, including pro-inflammatory cytokine production and
CD40 expression, to a similar degree as dexamethasone, without the immunosuppressive
effects on T cell mediated immunity that is normally associated with this drug. Taken
together, our research suggests that notoginseng possesses anti-inflammatory effects
without significantly affecting Ag-specific interactions between DCs and T cells. Thus,
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notoginseng may be an effective natural treatment for inflammatory diseases such as
arthritis, inflammatory bowel syndrome and asthma.
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CHAPTER 5.
An assessment of the immunotoxicological effects of Panax notoginseng in
ovalbumin immunized mice.

Unpublished Data
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Abstract
Many herbals have a long history of use and health claims that have not been confirmed
by scientific studies. As a result, there are numerous cases in which natural products not
only do not confer suggested benefits, but also cause harmful effects. There are a number
of studies characterizing the general toxicity of the popular herbal ginseng, but none that
was formulated specifically to examine whether ingestion of this natural product can
generate immunotoxicity. In this regard, the effects of high dose and low dose Panax
notoginseng treatment was studied in ovalbumin/alum immunized C57BL/6 and Balb/c
mice, respectively. Mice were gavaged for 10 days with either a high dose (1g/kg) or low
dose (660 µg/kg) notoginseng or PBS as control. On day 4 of notoginseng treatment,
mice were immunized with 100 µl of a mixture containing 20 mg ovalbumin and 2 mg
alum by i.p. injection. C57BL/6 and Balb/c mice were harvested 14 days and 12 days
post immunization, respectively. No effects on body, spleen and thymic weights were
observed between high or low dose notoginseng-treated and control groups. However,
there was a decrease in cell numbers in the mesenteric lymph nodes with high dose
notoginseng treatment. Additionally, ova-specific IgM levels were decreased after 7 days
of exposure to the high dose of notoginseng. Conversely, there were no effects on ovaspecific IgG levels on day 7 post-immunization. There were also no effects on IgG or
IgM levels at the later time point in either the high or low dose treatment groups. High
doses of notoginseng also decreased the ability of spleen cells to produce TNF-α after
restimulation with LPS ex vivo. Taken together, our results suggest that there is limited
immunotoxicity associated with high dose notoginseng exposure. However, this toxicity
is not present with low dose notoginseng treatment.
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Introduction
The roots of the Panax notoginseng plant have been traditionally used in Chinese
medicine because of their potential to treat a variety of ailments including inflammation,
cardiovascular diseases and cancer. Recently, there has been an increase in the use of this
plant and other herbals in Western countries including the US. The popularity of Ginseng
and other natural products is thought to be on the rise because of factors such as increased
availability over the Internet and other sources. Other reasons include an aging
population and experimenting with alternative treatment to alleviate symptoms of chronic
disease (Kinsel and Straus, 2003).
The safety and efficacy of many herbals have not been established. This is primarily
due to the 1994 Dietary Supplement Health and Education Act which classifies natural
products as foods. There are few studies characterizing the clinical efficacy of Ginseng
on a variety of conditions including diabetes and cancer (Carabin et al., 2000). However,
many of these studies are limited by the apparent differences in pharmacological effects
noted between Ginseng species (Kitts and Hu, 2000). Some studies suggest that there is a
low incidence of toxicity associated with ginseng intake (Carabin et al., 2000). There
have also been cases where Ginseng overdoses have been reported. This condition is
referred to as “ginseng abuse syndrome”. Nonetheless, there is some confusion as to the
validity of such a syndrome. This confusion is primarily caused by the lack of control or
analysis for the identification of the ginseng taken, or whether it was actually Ginseng or
another supplement that caused the toxicities in these patients (Carabin et al., 2000; Kitts
and Hu, 2000).
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The primary biologically active components of notoginseng are thought to be the
ginsenosides (Hasegawa, 2004). After oral ingestion these ginsenosides can pass through
the stomach without decomposition but are deglycosylated by colonic bacteria in the
large intestines prior to absorption. Following absorption, metabolites can be further
esterified with fatty acids by the liver to form additional bioactive derivatives. Studies
using rats suggest that the bioavailabilty of the intact ginsenosides is very low varying
from 0.1-18 percent.
Alterations in immune function can lead to several conditions, including increased
incidence of hypersensitivity disorders, autoimmune and infectious diseases or neoplasia
(Germolec, 2004; Selgrade, 1999). This change in immune function can result from
several synthetic or natural agents that can cause injury or insult to the immune system
(Delaney et al., 2001; Germolec, 2004). These agents are classified as immunotoxicants,
and are of considerable public health concern (Germolec, 2004). Potential
immunotoxicants are usually identified by using a variety of strategies to screen for their
harmful effects on the immune system. Tests include screening for changes in immune
organ weights, serum immunoglobulin levels and immune cell numbers (Germolec,
2004). Additional analyses include the quantitation of cell surface markers by flow
cytometry and cytokine production in immune cells in response to stimulation or
challenge (Germolec, 2004).
Notoginseng

has

diverse

immunomodulatory

properties

including

reducing

inflammation and boosting adjuvant activity (Sun et al., 2004). However, none of these
studies have formally explored the possible immunotoxicites that could arise from
notoginseng treatment. In this regard, the immunotoxicological effects of Panax
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notoginseng were examined using ovalbumin immunized Balb/c mice. Balb/c mice were
gavaged with a high or low dose of notoginseng or PBS controls and immunized with
ova/alum. During the treatment period, weight changes of the mice were assessed daily as
a measure of general toxicity between treatment and control groups. Mice were harvested
10 days post immunization and the weight and cell numbers, as well as cell surface
molecule expression of immune organs were examined for differences between
notoginseng and control groups. Spleen cells were stimulated with LPS ex vivo to
determine if notoginseng altered the immune responsiveness of these cells to an
inflammatory agent. Antigen specific antibody levels were also characterized in serum
collected from mice before immunization and immediately after harvesting. Our study
demonstrates that there is limited immunotoxicity associated with notoginseng intake.
Material and Methods
Animals
Two- to four- month old male C57BL/6 and Balb/c mice were bred and maintained in the
animal research facilities at the University of Montana. Mice were housed under specific
pathogen-free conditions and maintained on a 12-hour dark/light cycles. Standard
laboratory food and water were provided ad libitum. All protocols for the use of animals
were approved by the University of Montana Institutional Animal Care and Use
Committee.

Chemicals
Extracts were obtained from the roots of the Panax notoginseng (Burk.) F.H. Chen ex
C.Y. Wu & K.M. Feng plant using ethanol and standardized to contain Rb1 and Rg1
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ginsenosides at 35 and 34% of the whole extract, respectively. This resulting Noto-GTM
extract was kindly supplied by Technical Sourcing International, Inc. (TSI, Missoula,
MT). Levels of Rb1 and Rg1 in the notoginseng extract were determined by highperformance liquid chromatography analysis by TSI. Certification of analyses was
approved by Xia Ronglong (QA manager, TSI). There were no detectable amounts of
Escherichia coli (E. coli) or Salmonella enterica in the notoginseng preparation
(unpublished data). The extract was dissolved in complete media (see below) and
subsequently

sterile-filtered

through

a

0.22

µM

Millipore

membrane.

The

Lipopolysaccharide (LPS) from E. coli (055:B5) was obtained from Sigma-Aldrich.

Immunization
Balb/c mice were gavaged once daily for 10 consecutive days with either PBS (vehicle)
or a low dose (660 µg/kg) of notoginseng which was equivalent to concentrations which
the average person ingesting ginseng supplements would be exposed to. In a separate
experiment, C57BL/6 mice were gavaged with PBS controls or a high dose (1mg/kg) of
notoginseng. On day 4 of treatment, both BALb/c and C57BL/6 mice were immunized
with 100 µl of a mixture containing 20 mg ovalbumin and 2 mg alum (ova/alum) via I.P.
injections. Balb/c mice were harvested 11 days post immunization, (15-days after
notoginseng treatment), while C57BL/6 mice were harvested 14 days post immunization.
The thymuses, spleens, mesenteric (MLNs), popliteal (PLNs) and brachial (BLNs) lymph
nodes were removed from the animals for immunotoxicological analysis. Serum was also
collected from each mouse and used for measurement of antibody titers.
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Organ weights and cell counts
The spleens and thymuses were harvested and weighed for both the high dose and low
dose notoginseng treated groups. The spleens, MLN, PLN and BLN were processed and
cell numbers were calculated using a Coulter counter.
Preparation of spleen and lymph node cells
Single cell suspensions were prepared by pressing spleens or lymph nodes through cell
strainers using the tops of 1 ml syringes. Erythrocytes were removed from spleen cell
suspension by hypotonic lysis. Spleen and lymph node cells were then washed and
resuspended in RPMI (GibcoBRL, Grand Island, N.Y), supplemented with 10% FBS
(Hyclone, Logan, UT), 50 µM mercaptoethanol, 20 mM HEPES, 10 mM sodium
pyruvate and 50 µg/ml gentamicin (GibcoBRL, Grand Island, N.Y).
Flow cytometry
Detection of cell surface molecule expression on spleen and lymph node cells treated
with low dose notoginseng was analyzed by fluorescent activated cell sorting (FACS) as
previously described (Shepherd et al., 2001). Briefly, cells were harvested and washed
with PAB (1% bovine serum albumin and 0.1% sodium azide in PBS). Cells were
blocked with 30 µg of purified rat and/or hamster IgG (Jackson ImmunoResearch, West
Grove, PA) for 10 minutes to eliminate non-specific staining. Optimal concentrations of
flurochrome-conjugated murine monoclonal antibodies were used to stain cells for an
additional 10 minutes. The antibodies used in these experiments were CD4+, CD8+,
CD11b, CD11c, CD19, and their corresponding isotype controls (BDPharmingen, San
Diego, CA). One to five hundred thousand viable cells per treatment (as determined by
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light scatter profiles) were analyzed using a BD FACSAria flow cytometer and
FACSDiva software (BD Biosciences, San Jose, CA).

Measurement of OVA-specific antibody
OVA-specific antibodies for total IgG in serum were detected by indirect ELISA. Briefly,
96-well plates were coated with 100 µg/ml whole ovalbumin (diluted in dPBS) overnight
at 4 °C. The wells were washed three times with PBS containing 0.05% (v/v) Tween 20
(PBST), and blocked with 3% BSA/PBS for 2 hrs. Serum samples were added at 1:10-106
sequentially diluted samples. BSA/PBS (1%) was used as controls. The plates were then
incubated for 2 hrs. Aliquots of IgG (1:4000) and IgM (1:250) horseradish peroxidase
conjugate antibodies were added to each plate for an additional 1 hr. The plates were then
developed and the optical density (OD) was measured in a spectrophotometer reader at
450 nm.

Assay for cytokine production by spleen cells ex vivo
Spleen cells were incubated in RPMI (GibcoBRL, Grand Island, N.Y), supplemented
with 10% FBS (Hyclone, Logan, UT), 50 µM mercaptoethanol, 20 mM HEPES, 10 mM
sodium pyruvate and 50 µg/ml gentamicin (GibcoBRL, Grand Island, N.Y). Cell were
stimulated with LPS and harvested after 24 hrs. Supernatants were collected from the
LPS stimulated samples and the production of IL-6 and TNF-α were measured by
enzyme-linked immunosorbent assay (ELISA). Samples were analyzed according to the
manufacturer’s recommendations with mouse cytokine-specific BD OptEIA ELISA kits
(BD PharMingen, San Diego, CA).
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Results
Notoginseng treatment has no effects on the weights of mice
Biological processes, including the metabolism of chemicals, in humans and laboratory
animals are related to body weight (Huggett et al., 1996). As such, we first identified the
toxicity of notoginseng using changes in the weight of C57BL/6 (Fig. 5-1A) or Balb/c
(Fig. 5-1B) mice. Animals were gavaged with either a high or low dose of notoginseng
over a ten-day period (Fig. 5-1). Although there was the expected weight loss in both
control and notoginseng group immediately after immunization, there were no significant
changes in the weights of animals with either high or low dose notoginseng treatment
when compared to PBS control groups.

The effects of notoginseng on immune tissues
Alterations in the weight or cell number of immune tissue generally denote gain or loss of
cells by either changes in proliferation or cell viability. In these experiments, there were
no differences in organ weights of the spleens and thymuses in mice treated with either
high or low dose notoginseng (Fig. 5-2A/C). However, there was a decrease in the cell
numbers in the mesenteric lymph nodes in mice treated with a high dose of notoginseng
(Fig. 5-2B). Conversely, spleen, PLN and BLN cell numbers were unchanged with high
dose notoginseng exposure (Fig. 5-2B). No differences in cell numbers were observed in
any of the tissues tested after low notoginseng exposure (Fig. 5-2D).

Notoginseng differentially alters antigen specific antibody levels in Balb/c mice
The primary function of the immune system is to protect the body against pathogens.
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Figure 5-1.
A.

B.
Ova/alum

Ova/alum

Figure 5-1. The body weights of mice are unchanged by notoginseng (NG)
treatment. (A) C57BL/6 and (B) Balb/c mice were gavaged with low and high dose
notoginseng, respectively, or PBS controls. At day 4 of treatment mice were immunized
with ova/alum as previously described in the materials and methods section. Mice were
assessed daily for changes in body weight, and general overall health. Error bars indicate
mean ± SEM of 5 C57BL/6 and 6 mice Balb/c mice.
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Figure 5-2.

A.

C.

B.

D.

Figure 5-2. Notoginseng (NG) selectively affects cell numbers, but does not alter the
weight of immune organs in C57BL/6 and Balb/c mice. Mice were gavaged with low
(A,B) and high (C,D) dose notoginseng, or PBS controls and immunized with ova/alum
as previously described in the materials and methods section. At the end of the
experiment period, immune organs were harvested and analyzed for changes in weight,
and numbers. Error bars indicate mean ± SEM of 5 C57BL/6 and 6 mice Balb/c mice; *,
p < 0.05 for the comparison of PBS and notoginseng treated mice.
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After exposure to antigen, the innate immune system stimulates adaptive immune cells to
attack foreign antigens. In these experiments, mice that were exposed to notoginseng or
PBS were immunized with the adjuvant ova/alum to simulate exposure to a pathogen and
induce B cells to produce antigen specific antibody responses. Serum was collected from
mice gavaged with high dose notoginseng on days 7 and 17 after exposure (Table 5-1).
There was a 27 % decrease in IgM levels on day 7 of high dose notoginseng treatment.
However, there was no significant difference in IgG or IgM in either the control or
notoginseng treated group on day 17 of the experiment.
In Balb/c mice treated with a low dose of notoginseng, serum was collected only at the
end of the experiment period (day 15) (Table 5-2). There was no significant difference
between notoginseng and control treated mice in ova-specific IgG and IgM with low dose
exposure.
Notoginseng exposure elicits dose dependent differences in the sensitivity of splenocytes
to LPS stimulation ex vivo
The spleen is the largest secondary lymphoid organ and contains a variety of immune
cells including B cells and T cells, in addition to the APCs macrophages and DCs (Cesta,
2006; Elmore, 2006). Most of these cells respond to a stimulus such as LPS by a number
of mechanisms including the production of cytokines. As such, we examined the effects
of notoginseng on the response of spleen cells to the bacterial component, LPS. Spleen
cells from PBS controls and notoginseng treated groups were stimulated with 1 µg/ml
LPS for 24 hrs. As shown in Fig. 5-3A, TNF-α production was reduced by 25 % in the
high dose notoginseng treated group as compared to PBS control. There was also a
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Table 5-1. High Dose notoginseng treatment differentially affects antigen-specific
antibody generation in vivo
Antibody Type
IgG b

DAY 7 post initial NG exposure
PBS a
Notoginseng
0.58 ± 0.2
0.38 ± 0.15

DAY 17 post initial NG exposure
PBS
Notoginseng
0.58 ± 0.02
0.62 ± 0.07

IgM

0.36 ± 0.02

0.54 ± 0.25

a

0.26 ± 0.04*

0.28 ± 0.10

C57BL/6 mice were gavaged with a PBS controls or a high dose of notoginseng (NG)

(1g/kg) for 10 days. At 4-days of treatment mice were immunized with ova/alum by I.P
injections. Sera were collected from mice at 7 days and 17 days after notoginseng
exposure (3-days and 14 days post immunization, respectively).
b

Optical density (O.D.) for serum antibody levels as determined by ELISA.

c

Error bars indicate mean ± SEM of 5 mice; *, p < 0.05 for the comparison of PBS and

notoginseng treated mice.
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Table 5-2. The effects of notoginseng on ova-specific antibody production in Balb/c
mice
DAY 14 post initial exposure to NG
Antibody Type

PBS

Notoginseng

O.D IgG

0.40 ± 0.16

0.34 ± 0.12

O.D IgM

0.40 ± 0.08

0.33 ± 0.06

a

Balb/c mice were gavaged with a low dose of notoginseng (NG) (660 µg/kg) for 10

days. At 4-days of notoginseng treatment mice were immunized with ova/alum by I.P
injections. Sera were collected from mice at 14 days after notoginseng exposure (11 days
post immunization).
b

Optical density (O.D.) for serum antibody levels as determined by ELISA.

c

Error bars indicate mean ± SEM of 6 mice.
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Figure 5-3.

A.

C.

B.

D.

Figure 5-3. TNF-α production by LPS stimulated spleen cells is reduced by high
dose notoginseng (NG) exposure. (A, B) C57BL/6 and (C, D) Balb/c mice were
gavaged with low or high dose notoginseng, or PBS controls and immunized with
ova/alum as previously described in the materials and methods section. Cells from the
spleens of control and notoginseng treated mice were exposed to 1 µg/ml of LPS for 24
hours. Supernatants were harvested and analyzed for TNF-α and IL-6 production by
ELISA. Error bars indicate mean ± SEM of 5 C57BL/6 mice and 6 Balb/c mice; *, p <
0.05 for the comparison of PBS and notoginseng treated mice.
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trend towards decreased TNF-α production with spleen cells obtained from mice treated
with low dose notoginseng. This decreased trend was also observed with IL-6 production
with both high and low dose notoginseng.

The percentages of T cells, B cells, DCs and macrophages in immune tissues are not
altered by low dose notoginseng treatment
DCs and macrophages are important antigen presenting cells for initiating the activation
of T and B cells thereby eliciting adaptive immune response. To determine whether there
were any alterations in any of these populations by notoginseng treatment, cells were
obtained from the spleen, PBLN and MLN and stained for lineage marker cell surface
expression. There were no differences in the populations of DCs (CD11c+), macrophages
(CD11c-/ CD11b+), Th cells (CD4+), Tc cells (CD8+) or B cells (CD19+) with notoginseng
treatment as compared to PBS control groups (Fig. 5-4).
Discussion and conclusion
Immunotoxicology is the study of the adverse effects of natural and synthetic compounds
on the immune system. Exposure to an immunotoxicant can result in immune dysfunction
with outcomes including immunosuppression, or alternatively, allergy, autoimmunity or a
number

of

other

inflammatory

based

diseases.

Therefore,

identification

of

immunotoxicants is essential to maintaining homeostasis in an organism because of the
critical role the immune system plays in sustaining host resistance to microbes. In this
study, we evaluated the potential for notoginseng to elicit immunotoxicites in mice.
As chemicals can generate general toxicities if they affect multiple organs, we examined
weight changes in the tested animals throughout our experiment period.
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Figure 5-4.
A.

C.

B.

D.
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E.

Figure 5-4. Low dose notoginseng (NG) treatment does not alter the percentages of
APCs and T cells in the spleen and lymph nodes. Balb/c mice were gavaged with low
dose notoginseng, or PBS controls and immunized with ova/alum as previously described
in the materials and methods section. Based on lineage markers expression, cells from the
spleen, MLN and PBLN were analyzed for changes in the percentages of Th cells (CD4+),
T cytotoxic cells (CD8+), B cells (CD19+), dendritic cells (CD11c+) and macrophages
(CD11c- /CD11b+) by flow cytometry. Error bars indicate mean ± SEM of 6 Balb/c
mice.
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There were no changes in the weights of the mice at both concentrations of
notoginseng tested over a ten-day period, which is a good indication that acute doses of
notoginseng do not induce overt toxicity. Our results with notoginseng are in line with
previous studies that the LD50 for Panax ginseng in mice as high as 5g/kg for oral
administration (Carabin et al., 2000; Kitts and Hu, 2000).
Standard immunotoxicological tier testing involves assessing the weight of immune
organs after exposure to a potential immunotoxicant (Burns-Naas et al., 2001). The
thymus is one of the primary organs of the immune system. It is involved in “educating”
T cells for recognition of self and non-self antigens. The spleen is a secondary immune
organ, with the primary function of filtering the blood and removing both foreign
antigens and circulating dead cells. Both immune organs are therefore important for
optimal immune responses, and have been widely researched for toxicants which can
impair their functions. No changes in the weight of spleen or thymic organs were
observed at either dose of notoginseng examined. Changes in the weight of these organs
usually occur because of edema or an alteration in the proliferation of immune cell in
response to an immunotoxicant. As no differences were observed between treated and
control groups, we concluded that notoginseng does not alter the number of cells present
in these organs.
Lymph nodes are part of an immune network that filters antigens from interstitial
lymphatic fluid (Burns-Naas et al., 2001).The mesenteric lymph nodes are a part of the
gut associated lymphoid tissue (GALT), the intestinal branch of the body’s protection
against pathogens (Spahn et al., 2006). MLNs serve as sites where DCs prime T cells for
an immune response (Spahn et al., 2006). In our studies, decreased cell numbers were
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observed in the MLNs with high dose notoginseng exposure. However, no changes in cell
numbers were observed in the spleens and PBLNs, or with low doses of notoginseng. The
change in the MLNs may be due to these immune tissues being exposed to the highest
amounts of notoginseng constituents. Even after metabolism by gut flora, ginsenoside
concentrations would be highest in the GALT areas following oral administration of
notoginseng. This is because ginsenosides absorbed in the intestines have not yet been
decreased by first pass metabolism. The decreased cell numbers could have been due to
decreased ability of APC to induce T cell proliferation. Although we have not studied the
effects of notoginseng on macrophages and DCs after continuous exposure to
notoginseng, our previous studies demonstrated decreases in the activation and function
of these cells after a single exposure to this herbal (Rhule et al., 2006b). However, T cell
proliferation was not influenced by a single notoginseng treatment of DCs in these
studies. Therefore, experiments could be designed to examine if continuous exposure to
notoginseng could affect DCs ability to activate T cell proliferation. Additionally, it is
also possible that notoginseng or its derivatives induced necrosis or apoptosis of cells in
the MLNs leading to the observed decreased cell numbers.
The activation of B cells by soluble protein antigens such as ovalbumin requires the
involvement of T helper (Th) cells. The primary antibody type secreted after B cell
activation is IgM. In order for other types of antibodies to be secreted, B cells have to
undergo the process of class switching. This process cannot occur in B cells without
signals from Th cells such as CD40-CD40 ligand interactions. In our experiments, IgM
levels were decreased at the 7-day treatment time point (3 days post immunization) with
high doses of notoginseng. However, there were no changes in IgG levels at this time

139

point. This indicates that the effects of notoginseng may occur early in B cell activation
before class switching from IgM to IgG occurs. Additionally, because the entire animal
was exposed to notoginseng, it is unclear which immune cells or processes were directly
affected by treatment. Notoginseng exposure could have altered a number of events
including, antigen uptake, T cell interactions with B cells or their activation by APCs.
There were no differences in IgM or IgG levels between PBS controls and notoginseng
treated mice at day 17 of high dose and day 15 of low dose exposure. It should be noted
at this time-point notoginseng was no longer being administered to the mice, as the 10
days treatment period was completed. It is therefore possible that the effects were
“washed out” after a week of no treatment with notoginseng. Additional experiments
focusing on the levels of antibody present in both low dose and high dose notoginseng
mice over the entire treatment period are therefore warranted.
Previous studies indicated that notoginseng possesses adjuvant activity, increasing ova
specific antibody levels in mice after treatment (Liou et al., 2005; Sun et al., 2007; Yang
et al., 2007b). However, in our study ginseng reduced IgM levels at day 7 of high dose
notoginseng exposure, with a trend towards decreased IgG production at the end of the
experiment period in both high and low dose groups. The reason(s) for discrepancies
between our studies could have been due to a number of factors including differences in
the components of ginsenosides used in those studies compared to the sample of
notoginseng used in our experiment.
Cytokines are important mediators of an immune response. TNF-α and IL-6 are among
the first cytokines produced after immune stimulation. There was a reduction in TNF-α
production in spleen cells stimulated ex vivo with LPS in high dose notoginseng
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exposure, with an overall trend towards decreased cytokine production with both low and
high dose notoginseng treatment. These decreases in TNF-α and IL-6 are consistent with
our previous findings of reduced production of LPS induced pro-inflammatory cytokines
with notoginseng treatment (Rhule et al., 2006b; Smolinski and Pestka, 2003a)(submitted
article). In our previous studies, the effects of notoginseng on macrophages and DCs
were examined in RAW2467 cells and bone marrow derived dendritic cells, respectively.
As there are other cells present in the spleen that produce TNF-α and IL-6 in response to
LPS stimulation, it is possible that these cells are not as sensitive to notoginseng
treatment. Nevertheless, this possibility needs to be examined.
There were no changes in the cell surface molecule expression for any of the
molecules tested. As these molecules are classic lineage markers for identification of
different immune cell types, this suggests that none of the populations examined were
being altered by notoginseng treatment. Overall it gives a good indication that low dose
notoginseng treatment does not alter proliferation or increase apoptosis in the spleen,
BPLN or MLN.
Although there have been a number of toxicological studies in ginseng species,
studies on its immunotoxicological effects were not evident. In our study, we extended
the previous findings on the high LD50 associated with the Panax ginseng species, to
Panax notoginseng. Our study also established for the first time that there are no
immunotoxicological effects observed in mice treated with low dose notoginseng.
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CHAPTER 6
Panax Notoginseng reduces acetylated-LDL uptake by BMDCs

Unpublished data
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Abstract
Panax notoginseng has been purported to decrease the effects of conditions such as
diabetes mellitus, hypertension, hyperlipidemia and inflammatory diseases in a number of
studies. These abnormalities are all known risk factors for atherosclerosis. Uptake of
modified LDL by immune cells plays a major role in the early stages of atherosclerosis.
In this regard, the effects of notoginseng on acetylated LDL (ac-LDL) uptake were
examined. Bone marrow derived dendritic cells (BMDCs) were treated with notoginseng
and exposed to FITC-conjugated ac-LDL. Notoginseng decreased ac-LDL uptake by
immature BMDC as measured by flow cytometry. Furthermore, following stimulation
with the inflammatory cytokine TNF-α, notoginseng effectively attenuated ac-LDL
uptake by BMDCs. Expression of the accessory molecule CD40 was inhibited by
notoginseng on TNF-α treated BMDCs. These studies suggest that notoginseng has the
potential to alter uptake of modified LDL by antigen presenting cells.

Introduction
Inflammatory and immunologic mechanisms contribute to the initiation and progression
of atherosclerotic lesions (Kinlay and Egido, 2006). The earliest identifiable
atherosclerotic lesion is characterized by immune cell infiltration and lipid accumulation
(Hasham and Pillarisetti, 2006). These immune cells include activated macrophages,
dendritic cells and T lymphocytes (Link and Bohm, 2002) (Ohashi et al., 2004).
There are a number of antigens that are thought to be responsible for cellular immune
reactions in atherogenesis. Modified antigens such as oxidized low density lipoprotein
(ox-LDL) are among the major endogenous activators of the immune system (Link and

145

Bohm, 2002). In vitro studies have demonstrated that elevated levels of modified LDLs
including ox-LDL lead to activation and maturation of antigen presenting cells (APCs)
such as dendritic cells (DCs) (Link and Bohm, 2002; Lord and Bobryshev, 2002).
Activation of DCs by ox-LDL induces classic accessory/costimulatory molecule
expression including CD40, CD86 and MHC II (Cao et al., 2003). This initiates increased
T cell activation and proliferation, representing a chronic inflammatory response. This
process involves T lymphocytes recognizing ox-LDL, resulting in an autoimmune
response against cells bearing that antigen (Stemme et al., 1995).
The dietary supplement Panax notoginseng has been purported to have
immunomodulatory as well as cardiovascular properties. Previous studies in our lab
established that notoginseng reduced inflammatory mediatory production by both DCs
and macrophages in vitro (Rhule et al., 2006b)(unpublished data). In a study with Wistar
male adult rats on a fat-enriched diet, treatment with notoginseng decreased the total
cholesterol and triglycerides present in the blood (Cicero et al., 2003). Additionally,
notoginseng has also been demonstrated to reduce high blood pressure (Lei and Chiou,
1986). To date, there have been no studies examining the effects of notoginseng on
modified-LDL uptake and atherosclerotic plaque formation. As both of these events have
been demonstrated to have immune and cardiovascular components, we investigated the
effects of notoginseng on ac-LDL uptake by bone marrow derived dendritic cells
(BMDCs). BMDCs were treated with notoginseng and exposed to FITC-conjugated acLDL, a modified lipoprotein that is similar to ox-LDL, but more stable. In some
experiments, BMDCs were exposed to the pro-inflammatory cytokine TNF-α, in
conjunction with ac-LDL to simulate a mild inflammatory condition. Following
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notoginseng treatment, levels of ac-LDL uptake and expression of the activation
molecule CD40 on BMDCs were characterized by flow cytometry. Our study
demonstrates that notoginseng reduces the uptake of ac-LDL by BMDCs and provides
information on potential uses of this herbal for the treatment of atherosclerosis.

Materials and Methods
Mice
Male and female C57BL/6 mice aged 4-8 weeks old were bred and maintained in the
animal research facilities at the University of Montana. Mice were housed under specific
pathogen-free conditions and maintained on 12-hour dark/light cycles. Standard
laboratory food and water were provided ad libitum. Protocols for the use of animals
were approved by the University of Montana Institutional Animal Care and Use
Committee.

Cells
Bone marrow cells (BMCs) were collected from the femur and tibia of C57BL/6 mice for
in vitro use and differentiated in BMDCs as previously described in Chapter 4. Briefly,
BMCs were grown in cRPMI with 30 ng/ml granulocyte-macrophage colony stimulating
factor (GM-CSF), (Leinco, St Louis, Missouri) at 1X10

6

cells per ml in T75 flasks.

Media and growth factor were replaced on days 3 and 5. Cells were harvested after 7
days and DCs purified (>90%) using CD11c-APC antibodies and anti-APC Miltenyi
magnetic beads (Miltenyi Biotec, Auburn, CA) according to the manufacturer’s
instructions.
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Chemicals
Noto-GTM extracts were kindly supplied by Technical Sourcing International, Inc. (TSI,
Missoula, MT). Panax notoginseng (Burk.) F.H. Chen ex C.Y. Wu & K.M. Feng extracts
was acquired from the root of the plant using ethanol and standardized to contain Rb1
and Rg1 ginsenosides at 35 and 34% of the whole extract, respectively. The
quantification of Rb1 and Rg1 in the notoginseng extract was determined by highperformance liquid chromatography analysis by TSI. Certification of analyses was
approved by Xia Ronglong (QA manager, TSI). Levels of Escherichia coli (E. coli) or
Salmonella enterica were undetectable in the notoginseng preparation (unpublished data).
The extract was dissolved in complete media (see below) and subsequently sterile-filtered
through a 0.22 µM Millipore membrane. Acetylated FITC-conjugated LDL and TNF-α
were obtained from Molecular Probes (Eugene, OR) and Peprotech Inc (Rock Hill, NJ),
respectively.

Cell Activation and Treatment
BMDCs (1 X 106 cells per well) were treated with 0 or 200 µg/ml of notoginseng and/or
stimulated with TNF-α (10ng/ml) for 24 hrs at 37 0C and 5% CO2 in 6-well plates. At 22
hrs of treatment, cell were incubated with 1 µg/ml ac-LDL for the last 2 hrs. Cells were
harvested for FACS analyses. The viability of BMDCs used in all experiments was
greater than 90% as determined by Trypan blue exclusion.
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Flow Cytometry
Accessory molecule expression and fluorescent molecule uptake by BMDCs were
performed by fluorescent activated cell sorting (FACS) analysis as previously described
(Rhule et al., 2006b; Shepherd et al., 2001). Briefly, BMDCs that were previously
incubated with FITC-conjugated ac-LDL were harvested and washed with PAB (1%
bovine serum albumin and 0.1% sodium azide in PBS). Cells were blocked with 30 µg of
purified rat and/or hamster IgG (Jackson ImmunoResearch, West Grove, PA) for 10
minutes to eliminate non-specific staining. Flurochrome-conjugated monoclonal
antibodies were used to stain cells for an additional 10 minutes. The antibodies used in
these experiments were CD40-PE, CD11c-APC and their corresponding isotype controls
(BDPharmingen, San Diego, CA). One hundred thousand viable cells per treatment (as
determined by light scatter profiles and propidium iodide staining) were analyzed using a
BD FACSAria flow cytometer and FACSDiva software (BD Biosciences, San Jose, CA).

Statistics
All statistical analyses were performed using GraphPad Prism 4.0a for the Macintosh
(GraphPad Software, San Diego, CA). Data represents the mean ± SEM of 3 samples for
3 independent experiments unless otherwise stated. Differences between treatment groups
were analyzed by Student’s t-test. Data sets with multiple comparisons were evaluated by
one-way analysis of variance (ANOVA) with Dunnett’s test. Values of p < 0.05 were
determined to be significant.
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Results
Notoginseng reduces ac-LDL uptake by BMDCs
DCs are specialized innate immune cells with the ability to phagocytose antigens
(Niedergang and Chavrier, 2005). Transformed-LDL has been recognized as one of the
primary antigens present in the development of atherosclerotic lesions. In this regard,
DCs were treated with 200 µg/ml notoginseng and exposed to FITC-conjugated ac-LDL.
There was a significant increase in the fluorescence intensity of BMDCs exposed to acLDL (Fig 6-1). Notoginseng reduced the uptake of ac-LDL by 30% when compared to
untreated controls (Fig 6-1A). In some experiments, cells were exposed to TNF-α as this
cytokine is associated with inflammatory responses within atherosclerotic plaques.
Notoginseng decreased uptake of ac-LDL by TNF-α-treated BMDCs (Fig 6-1B).

CD40 expression on TNF-α-treated BMDCs is decreased by notoginseng
CD40 is a cell surface protein that is constitutively expressed on DCs and other APCs
and is upregulated during inflammation (Lutgens et al., 2007). The interaction of CD40
and its ligand plays a significant role in the development and progression of
atherosclerosis (Lutgens et al., 2007). Therefore, we examined the effects of notoginseng
on the expression of CD40 on TNF-α-treated BMDCs after exposure to ac-LDL. CD40
expression was decreased on the notoginseng-treated BMDCs exposed to ac-LDL when
compared to TNF-α-treated ac-LDL controls (Fig 6-2).
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Figure 6-1.
A.

B.

Figure 6-1. Notoginseng impairs ac-LDL uptake. BMDCs were treated with 200 µg/ml
notoginseng and/or stimulated with TNF-α for 24 hrs. Cells were exposed to FITCconjugated ac-LDL 2 hrs prior to harvesting. Uptake of (A) ac-LDL and (B) ac-LDL by
TNF-α-treated BMDCs was assessed by flow cytometry. Data represents mean ± SEM of
three samples. # indicates significant differences between LDL-exposed and unexposed
cells; * indicates significant differences between LDL-exposed control- and notoginsengtreated samples (p<0.05). Data are representative of three independent experiments.
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Figure 6-2.

Figure 6-2. CD40 expression is reduced by notoginseng on TNF-α-treated BMDCs
exposed to ac-LDL. BMDCs were treated with notoginseng and TNF-α for 24 hrs and
then exposed to FITC-conjugated ac-LDL for an additional 2 hrs. The expression of the
costimulatory molecule CD40 was assessed by flow cytometry. Data represents mean ±
SEM of three samples. # indicate significant differences between LDL-exposed and
unexposed cells; * indicates significant differences between the LDL-exposed controland notoginseng-treated samples (p<0.05). Data are representative of three independent
experiments.
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Discussion and conclusion
Development of atherosclerotic plaques involves complex interactions between the
endothelium, inflammatory cytokines, and numerous blood cells and components (Libby,
2004). Notoginseng has been shown to decrease inflammatory mediator production by a
variety of immune cells. In this study, we investigated the effects of notoginseng on acLDL uptake by BMDCs. Using two models of exposure, notoginseng reduced ac-LDL
uptake under non-inflammatory and mild inflammatory conditions. Exposing BMDCs to
ac-LDL in the absence of TNF-α models the effects of notoginseng on antigen uptake.
However, there is considerable evidence that cytokines such as IL-1, IL-6, and TNF-α
are involved in the formation of atherosclerotic plaques (Libby, 2004). In addition
expression of cell surface molecules such as CD40 by cells in the plaque region fuels the
inflammatory process by further leukocyte recruitment (Libby, 2004). Exposure of TNFα-treated BMDCs to ac-LDL allows examination of the effects of notoginseng on antigen
uptake during inflammatory conditions that would be expected in an atherosclerotic
plaque. In our experiments, uptake of ac-LDL was reduced in notoginseng-treated
BMDCs. Furthermore, CD40 expression was reduced on the notoginseng-treated
BMDCs. This might lead to decreased activation of other immune cells within the plaque.
However, this possibility remains to be examined.
Because notoginseng effectively reduced the uptake of ac-LDL by BMDCs, its
potential to alter atherosclerotic plaque formation in ApoE/LDL receptor double
knockout mice was evaluated (data not shown). These mutant mice are prone to develop
atherosclerotic plaques (Bunderson et al., 2004). In these experiments ApoE-/-/LDLr-/mice were orally dosed with 2.5 mg/ml of notoginseng in their drinking water over a ten-
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week period.

Unfortunately, plaque formation at the harvest (ten weeks) was not

substantial enough to draw a conclusion between control-and notoginseng-treated mice.
Therefore, these studies are presently being expanded to a time point of twenty weeks to
facilitate more pronounced plaque formation.
Collectively, our data demonstrate that treatment of dendritic cells with notoginseng
reduces their ability to phagocytose modified LDL. Furthermore, expression of the costimulatory molecule, CD40, was decreased by notoginseng on ac-LDL-treated BMDCs.
Our results demonstrate that notoginseng may have the potential to decrease phagocytic
activity of DCs in atherosclerotic plaque formation and provide provocative information
on the use of this herbal for the potential prevention or treatment of cardiovascular
disease.
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CHAPTER 7
Summary
In 1991 the NIH launched its office of Complementary and Alternative Medicine
(now the National Center for Complementary and Alternative Medicine) in response to
the public’s huge interest in non-conventional medicine (http://nccam.nih.gov/, ; Kinsel
and Straus, 2003). One of the largest subsidiaries of the alternative medicine group is
dietary supplements, primarily the herbal products division (http://nccam.nih.gov/). Of
these herbals, ginseng was the second most widely used by the U.S. population in 2002.
Ginseng

is

purported

to

have

numerous

pharmaceutical

effects

including

immunomodulation, lowering blood sugar and reducing hypertension (Carabin et al.,
2000; Kitts and Hu, 2000; Lei and Chiou, 1986). However, the safety and efficacy of this
herbal product has not been extensively examined. To address aspects of this deficiency
we examined the immunomodulatory effects of Panax notoginseng on the fate and
function of APCs. We hypothesized that notoginseng alters APC fate and function by
decreasing activation molecule expression and inflammatory mediator production by
macrophages and DCs. Furthermore, we believe that these effects may be exploited to
treat immune-related diseases such as atherosclerosis and rheumatoid arthritis. As such,
we characterized the immunonomodulatory effects of notoginseng on APCs, the
incidence of toxicity for notoginseng and eventually extended our studies to examine the
effects of notoginseng on LDL uptake and atherosclerotic plaque formation in a mouse
model.
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In our study we examined the effects of notoginseng on APCs using the murine
marophage cell line RAW264.7, the dendritic cell line DC2.4 and primary BMDCs. As
cytokines are important mediators of the inflammatory response, changes in the
production of these proteins were initially assessed (Andreakos et al., 2004b).
Notoginseng reduced the LPS induced production of the pro-inflammatory cytokines
TNF-α and IL-6 in RAW264.7, DC2.4 and BMDCs. The use of BMDCs also afforded us
the opportunity to test IL-1β and IL-12 levels which were not produced in detectable
amounts in the immortalized cell lines. The production of these cytokines was also
inhibited by notoginseng.
Accessory molecule expression is integral for APCs to perform their primary function
of activating T cells (van Kooten and Banchereau, 2000). In our experiments, expression
of the key costimulatory molecules CD40 and CD86 was decreased on RAW264.7 and
DC2.4 cells stimulated with LPS. However, CD86 proved not to be as sensitive to
notoginseng treatment and required pretreatment of BMDCs to significantly affect its
expression. In addition, MHC II expression was also not altered by concurrent treatment
of BMDCs with notoginseng and LPS stimulation, but was decreased with pretreatment.
Inflammatory mediator production can be induced in immune cells via activation of
toll-like receptors (TLRs) including TLR3, TLR4 and TLR9. In our studies, notoginseng
attenuated TNF-α production and CD40 expression induced by TLR3, 4 and 9 activation
in DC2.4 cells. Alternatively, CD86 expression was reduced by notoginseng when DCs
were activated with ligands to TLR 3 and 4, but not TLR 9. Also, IL-6 production by
notoginseng-treated cells stimulated with LPS and CpG was reduced when compared to
controls. TLR 3 ligand-stimulated DCs were unaffected by notoginseng treatment. While
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we do not fully understand the differential effects notoginseng on APCs, it is clear that
DC responses to TLR ligands are affected by this herbal extract.
Inflammatory enzymes mediate immune responses by the synthesis of proteins or
molecules capable of modulating the immune system. The mRNA expression of COX-2
was inhibited by notoginseng in RAW264.7 cells. Previous studies in our lab also
established that the activity of COX-1/COX-2 was inhibited by notoginseng (Seaver and
Smith, 2004). Future experiments should be carried out to examine if notoginseng might
affect prostaglandin levels in DCs.
Activation of the transcription molecule NFκB results in inflammatory mediator
production by APCs. Notoginseng reduced the LPS-induced nuclear levels and activity of
the p65 component of NFκB in BMDCs. Future studies should examine whether other
transcription factors such as Rel B and c Rel components of NFκB, as well as non-NFκB
mediated pathways such as AP-1 are also affected by notoginseng.
A primary function of APCs is to phagocytose antigens for presentation to T cells. In
this regard, we examined whether notoginseng affected antigen uptake by DCs.
Notoginseng reduced ovalbumin antigen uptake by BMDCs. As antigen uptake as well as
inflammatory mediator functions were impaired by notoginseng, we designed studies to
examine whether notoginseng could alter the ultimate fate of DCs, the activation of
antigen-specific T cells. Our studies demonstrated that notoginseng did not affect DC
activation of antigen-specific T cells in vitro or in vivo.
Therefore, notoginseng reduced the production of inflammatory mediators and innate
responsiveness by APCs, but did not affect the initiation of T cell-mediated adaptive
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immunity. The long-term implications of our results suggest that notoginseng might be a
natural product capable of treating various inflammatory diseases.
Based on these results, we subsequently evaluated if notoginseng generated any
associated general toxicities or immunotoxic effects. Studies on the effects of high dose
and low dose notoginseng treatment in mice showed limited toxicities following oral
consumption of notoginseng. Moreover, these toxicities were only observed at the high
dose of notoginseng tested.
Finally, we evaluated the effects of notoginseng on atherosclerosis, an important
disease contributing to morbidity and mortality in developed countries (Keaney, 2000).
Initial studies in our lab demonstrated that treatment of BMDCs with notoginseng
resulted in decreased uptake of acetylated-LDL (ac-LDL). Additional experiments have
been implemented to determine whether notoginseng decreases plaque formation in
ApoE/LDL receptor, double knockout mice, which are prone to develop atherosclerotic
plaques. Future studies in our lab will characterize the effects of notoginseng on plaque
formation in these mice. The effects of notoginseng on the concentrations of
inflammatory mediators in the serum of treated mice will also be analyzed.
In conclusion, notoginseng decreased the innate and inflammatory functions of APCs
without altering their fundamental fate of activating antigen-specific T cell activation.
Our studies demonstrate a low incidence of immunotoxicity associated with notoginseng
consumption in mice. Taken together, our research highlights the potential usefulness of
notoginseng in the treatment of inflammatory diseases. Future studies should characterize
the specific mechanisms of action of notoginseng, and how this popular medicinal herbal
can be exploited to treat diseases.
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